SuperCom (NASDAQ: SPCB) Helping Lead Electronic Monitoring Industry into Future Following California Contract

August 29, 2023 10:34:12
  • SuperCom, through its fully-owned subsidiary, Leaders in Community Alternatives (“LCA”), just closed a multi-million dollar contract in California that will run until 2026
  • The contract marks another substantial achievement for SuperCom, building on a track record of securing numerous electronic monitoring contracts in the U.S. and Europe
  • The company’s management notes how well it is positioned to help the electronic monitoring industry move into the future

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity security solutions offering advanced safety, identification, and security products and solutions to governments, just closed a multi-million dollar contract in California. The contract, secured through SuperCom’s fully-owned subsidiary, Leaders in Community Alternatives (“LCA”), will see the company provide alcohol monitoring technologies and services in the state and will run until 2026, including an initial 3-year period with the potential for future extensions (https://ibn.fm/g8Kuh).

“Our reputation for providing reliable and high-quality electronic monitoring services was pivotal in securing the contract,” noted Ordan Trabelsi, SuperCom’s President and CEO. “We are proud to have…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Freight Technologies (NASDAQ: FRGT) Continues ‘Pushing the Boundaries of Innovation’ with AMACARGA Membership

August 28, 2023 11:46:48

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and increasing shipper flexibility, visibility and simplicity, recently joined the Mexican Association of Cargo Agents (“AMACARGA”). “This is viewed as a strategic move by the company that will expand its capabilities to cater to the growing demands of its clients importing goods from Asia. AMACARGA is the largest association of cargo agents in Mexico, an authoritative voice among Mexican and international chambers, associations and authorities. Fr8Tech’s association with it affords it exceptional expertise and adherence to industry standards, a critical aspect in bolstering its reputation as a reliable and trustworthy freight solution provider,” a recent article reads. “We are excited to join AMACARGA, a prestigious institution in the field of cargo agents,” Javier Selgas, Fr8Tech’s CEO, is quoted as saying. “This membership will help us expand the footprint of offerings to our clients, validate our continuous efforts to revolutionize the logistics industry, and underscores our unwavering commitment to delivering cutting-edge solutions to our clients. We remain dedicated to pushing the boundaries of innovation and providing exceptional service, consistently exceeding the expectations of our valued customers.”

To view the full article, visit https://ibn.fm/SUtKc

About Freight Technologies Inc.

Freight Technologies (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a B2B cross-border shipping marketplace in the USMCA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, please visit Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

BiondVax Pharmaceuticals (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17

August 28, 2023 11:46:18

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (“IL-17”) for the treatment of psoriasis, HS and other important indications. “BiondVax is now fast on the trail of developing what could be a very promising drug. Autoimmune diseases are often chronic and require patients to take drugs for life, with annual sales for current anti-interleukin-17 monoclonal antibodies totaling about $7.5 billion. With their NanoAbs, BiondVax aims to generate a highly potent, highly specific drug that is safe to use for the large and underserved population of mild-to-moderate psoriasis patients. BiondVax expects to complete a proof-of-concept trial later this year, followed by human clinical trials,” a recent article reads. “BiondVax CEO Amir Reichman explained that there are currently several treatment options on the market for psoriasis patients, such as, for example, creams and other topical drugs, biologics, and oral drugs for plaque psoriasis patients. However, the topicals are not highly sophisticated drugs, and they come with considerable side effects… As for biologics, they are highly potent, but they are restricted to moderate and severe cases of psoriasis, which accounts for only 15% of patients with psoriasis.”

To view the full article, visit https://ibn.fm/l1ZOm

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Fintech Ecosystem Development (NASDAQ: FEXD) Helping Advance a Cashless Society

August 28, 2023 11:45:58

Fintech Ecosystem Development Corp. (NASDAQ: FEXD), a special purpose acquisition company (“SPAC”), is focused on the changing consumer landscape and how digital payments are shaping the way people transact. “In response, the company is pushing for the creation and proliferation of much-needed scalable access to systems and infrastructure that facilitate cashless payments, ultimately playing an integral role in advancing a cashless society, both in the U.S. and around the world,” a recent article reads. “The growing preference for digital payments is clear, and nothing new, but it still has huge opportunities for the future. The company, through its aggressive yet strategic acquisition approach, is building a global network of mobile money platforms, applications, technologies, products, and services, that together make it easy and highly efficient to move money across borders to almost any corner of the world. Currently, the company services more than 50 currencies, with customers enjoying low conversion costs, further adding to the product’s accessibility.”

To view the full article, visit https://ibn.fm/fYu9T

About Fintech Ecosystem Development Corp.

Fintech Ecosystem Development is a special purpose acquisition company formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector. The company is sponsored by Revofast LLC and the management team led by CEO, president and founder Dr. Saiful Khandaker and a group of experienced fintech business and technology innovators. For more information about the company, please visit www.FintechEcosys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Receives Class 3 Vehicle PO from NRTC Automation Group

August 28, 2023 11:45:33

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has received a multiunit vehicle purchase order from NRTC Automation Group for three all-electric commercial class 3 Mullen trucks; the announcement noted that delivery of the vehicles is scheduled to begin in Q4 2023. Alabama-based NRTC, which has locations in South Carolina, Michigan and Ontario, provides turnkey automation, prototyping and production manufacturing solutions for the automotive industry. Mullen noted that the Mullen THREE is an efficient class 3 low-cab, forward EV truck featuring an 11,000 gross vehicle weight rating as well as a turning diameter of 38 feet and excellent visibility for superior maneuverability. The vehicle chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and payloads of more than 5,800 pounds. NRTC officials noted that they had had an opportunity to sit in the vehicle and test drive it at Mullen’s commercial launch last week and that the company has several applications where the Mullen THREE will be an ideal fit. “We are very excited to announce this vehicle purchase order for our Mullen THREE with NRTC,” said Mullen Automotive chief commercial officer John Schwegman in the press release. “Mullen is focused on providing solutions for fleets of all sizes as the adoption of electric vehicles increases.”

To view the full press release, visit https://ibn.fm/tD3EL

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Renovaro BioSciences (NASDAQ: RENB) Aims to Unlock Potential Treatments for Infectious Diseases, Cancer

August 25, 2023 11:24:37
  • Renovaro’s current product development pipeline includes a variety of treatment candidates spanning cancer, HIV, and HBV
  • Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat
  • The company recently entered into an LOI with GEDi Cube that could enhance the efficacy of upcoming trials and speed up delivery results

As an advanced, pre-clinical biotechnology company specializing in cell, gene, and immunotherapy, Renovaro BioSciences (NASDAQ: RENB), formerly Enochian BioSciences Inc., aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (“HIV”) and Hepatitis B Virus (“HBV”) infection.

Renovaro’s oncology platform is now at the forefront of the company’s development activities – primarily focused on pancreatic cancer. The company also plans to include other solid tumors with short life expectancy in the first human Phase I/IIa studies that are on track for…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

SuperCom (NASDAQ: SPCB) Announces ‘Breakthrough Performance’ with Q2 2023 Results

August 25, 2023 11:23:59
  • SuperCom recently released its second quarter and first half 2023 results for the period ended June 30, 2023
  • Financial highlights included a 141% YoY increase in quarterly revenue and a 126% YoY increase in half-year revenue to $7.7 million and $14.1 million, respectively
  • The company reported a 106% increase in trailing-twelve-month revenue to $25.5 million from $12.4 million
  • SuperCom provided business highlights, documenting its recently awarded contracts and projects in Europe (Romania, Finland, and Iceland) as well as in the US
  • President and CEO Ordan Trabelsi credits the company’s investments in research and development as well as sales and marketing for its ability to land global opportunities and displace incumbents

SuperCom (NASDAQ: SPCB), a global provider of traditional and digital identity solutions, providing advanced safety, identification, Internet of Things (“IoT”), connectivity, and security solutions to governments and private and public organizations globally, recently released its financial and operating results for the three and six months ended June 30, 2023, as well as financial highlights for the trailing-twelve-month period (https://ibn.fm/7seN6).

“We are excited to announce breakthrough performance for Q2 2023, where we outperformed expectations on multiple fronts. Our efforts have catapulted us to new heights, realizing a substantial 141% year-over-year (“YoY”) revenue growth, as well as record-breaking quarterly revenue of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Knightscope, Inc. (NASDAQ: KSCP) Inks Two New Deals in Texas

August 25, 2023 11:23:30

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, announced two new contracts: one for three K1 Hemispheres and one for a K1 Blue Light Tower. Both customers are based in Texas. According to the announcement, the first contract was from one KSCP’s resellers, a Houston-based security company that provides custom-tailored security services for clients of all sizes.

The contract is a preorder for three of Knightscope’s new K1 Hemisphere ASRs to be installed in a gated golf community in central Texas. The company has announced that its Hemisphere ASRs are in the final stage of testing, and it is preparing to fulfill preorders.

The second contract is with an existing Knightscope customer in San Antonio. The contract calls for an expansion of the customer’s K1 Blue Light Tower (“K1BLT”) emergency communication device system. With the new contract, Knightscope has 16 K1BLT devices patrolling a variety of park areas. “Blue light towers and emergency phones provide one-touch access to first-response services and expand the reach of emergency assistance to those utilizing park areas by providing lifelines to people who may be experiencing some form of emergency, crisis or distress,” the company stated in the press release.

To view the full press release, visit https://ibn.fm/Nu4AU

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN) Hosts Launch Event Marking Class 3 Vehicle Production

August 25, 2023 11:23:09

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, held its first-ever open house at its Tunica manufacturing facility. The event marked the company’s first Class 3 EV trucks rolling off the assembly line. According to the announcement, the event provided attendees with the opportunity to tour the Tunica site, enjoy a company presentation, and test drive MULN’s class 1 and class 3 commercial vehicles. Local county and state leaders, members of the media, investors and customers attended the event. The company anticipates ramping up production of its class 3 vehicles throughout the remainder of this calendar year, with full production capacity currently planned at 3,000 class 3 vehicles annually per shift. The company noted that as EV adoption rates increase, it has the capacity to add a second shift, which will increase capacity of the class 3 EVs to 6,000 total vehicles per year. At the same time, the company is also conducting production testing and launch of the Mullen ONE, class 1 EV Cargo Van at the Tunica plant. Delivery on both vehicles is expected to begin by year end. “Whenever a new vehicle program hits this stage, it’s great that we can bring key people to the plant like we did today with our dealer, Randy Marion, and first customer, MGT, so they feel the excitement firsthand and see the reality that our vehicles are heading their way very soon,” said Mullen Automotive chief commercial sales officer John Schwegman in the press release.

To view the full press release, visit https://ibn.fm/5XHPk

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen I-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

RVL Pharmaceuticals (NASDAQ: RVLP) to Participate at H.C. Wainwright Global Investment Conference

August 24, 2023 10:11:05

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, will be represented at the 25th annual H.C. Wainwright Global Investment Conference. The company announced that CEO Brian Markson will be participating in a fireside chat during the event, which is scheduled for Sept. 12, 2023. Markison will also be hosting one-on-one investor meetings during the conference, which will be held in New York City. Markison’s fireside chat is slated to begin at 11:30 a.m. ET. and can be viewed by webcast, either live or following the event on a replay.

To view the fireside chat, visit https://ibn.fm/STi56

To view the full press release, visit https://ibn.fm/VeB9l

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first nonsurgical treatment option approved by the FDA for acquired blepharoptosis. For additional information about this company, please visit www.RVLPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Lexaria Bioscience (NASDAQ: LEXX) Eyes Launching IND Program on DehydraTECH-CBD for Hypertension

August 24, 2023 10:10:31

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been published in eight peer-reviewed articles across six different publications. “The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is ‘Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study.’ The addition of this research article builds on the growing body of peer-reviewed literature developed by Lexaria’s leading research team into the effects of DehydraTECH-CBD and human health,” a recent article reads. “We’re proud of the impressive amount of research that our company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers,” John Docherty, president of Lexaria, is quoted as saying. “Lexaria is establishing itself as one of the world’s leaders in the investigation of cannabidiol for the purposes of controlling human blood pressure, and we are now focused on launching an FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year.”

To view the full article, visit https://cnw.fm/Qb2PJ

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Renovaro BioSciences (NASDAQ: RENB) Eyes Clear Path to IND Submission for Cancer Platform

August 24, 2023 10:10:02

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application (“IND”) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the U.S. Food and Drug Administration (“FDA”) on the company’s Pre-IND submission. The company’s proprietary, novel technology uses cell- and gene-therapy to promote renewed immune response against solid tumors. “We are grateful to the FDA for the very timely, thorough and clear direction that was provided. After a comprehensive review by our management, scientific, regulatory, and clinical operations teams, we believe we have a clear path forward to submit an IND in early/mid 2024 with clinical trials potentially beginning in first half of 2024,” said the company’s CEO Dr. Mark Dybul.

To view the full press release, visit https://ibn.fm/HfbZe

About Renovaro BioSciences Inc.

Renovaro BioSciences, formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as human immunodeficiency virus (“HIV”) and hepatitis B virus (“HBV”) infection. For more information, visit the company’s website at https://enochianbio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) CEO Issues Open Letter to Shareholders

August 24, 2023 10:09:38

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today shared an open letter to its shareholders addressing declining stock values. “The company has received numerous requests to respond to the ongoing decline of our stock. Many of these communications have been addressed to me personally with less than kind, and sometimes threatening statements. As CEO of this company, I take all shareholders’ concerns seriously. One of my primary responsibilities is to execute the company’s business plan, and as evidenced by multiple prior communications to the public, the company continues to make significant strides in that regard. I will summarize some of those at the end of this statement,” writes Mullen CEO and Chairman David Michery.

“I am very disappointed by the performance of our stock. As I have previously publicly stated, I do not believe the trading price of our stock even closely resembles the company’s actual value. It is evident that, regardless of meeting significant corporate milestones (i.e., vehicle production completion within projected timelines), stock traders continue to place downward pressure on the stock, causing the price to fall. I previously announced that the company engaged Share Intel and other parties to investigate what I suspect to be unlawful trading practices in our stock. We are assembling all the data received to date and should have something to announce in the coming days. I am extremely frustrated that the hard work of Mullen‘s dedicated team and the significant momentum and successes achieved to date are overshadowed by the unrealistic value attributed to our stock. The company and I have demonstrated our commitment to the success of our initiatives by purchasing its stock through the previously announced Share Buy Back program. I have also personally recently purchased stock, demonstrating my unwavering confidence in our company. I remain committed to executing the company’s business plan and using all measures at our disposal to eliminate any unlawful trading practices in our stock.”

To view the full news release, visit https://ibn.fm/5m40Q

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) Announces Contracts with Casino Client for K1 Tower, K1 Hemisphere

August 23, 2023 11:59:06

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has inked two new contracts with a northern California casino. Noting that the company “wins jackpot” with its new casino client, Knightscope announced that it has contracted with the casino for one K1 Tower as well as a pre-order for two K1 Hemisphere ASRs.

The K1 Hemisphere contract is the latest in a growing number of pre-orders that Knightscope has received for its newest ASRs. Most recently, the company deployed two K1 Hemispheres in Hawaii as the new devices enter the final stage of testing before beginning fulfillment of existing pre-order contracts.

The K1 Tower is a stationary indoor/outdoor ASR that is ideal for use at smaller properties where mobility is not necessarily required; it is also great for patrolling points of ingress and egress. The device operates 24/7 and includes many of the same features that KSCP’s mobile ASRs have become known for, including the added option of facial recognition.

The K1 Hemisphere is a compact ASR, making it a perfect complement to its bigger ASR siblings. The device is an ideal option for casinos, commercial property owners, residential communities, bank ATM vestibules, truck stops, lobbies, loading docks, ports, rail, schools and other locations where elevating security and safety is the goal. The Hemisphere can be mounted to a variety of objects, including poles, fences, buildings, walls, and more.

To view the full press release, visit https://ibn.fm/lFcgX

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Renovaro BioSciences (NASDAQ: RENB) Announces Intention to Unite With AI Tech Developer GEDi Cube

August 23, 2023 11:58:27
  • Combination of advanced AI machine learning technology and proven immunotherapy technology seen as “future of medicine”
  • Demonstrated success that both companies have shown with their innovative developments is expected to expand synergistically
  • Potential applications against variety of cancers

The announcement of a binding and exclusive letter of intent to merge, between two of the most innovative companies in their respective fields, is seen as representing a potentially transformative step in the fight against cancer. Considering Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy, that has already demonstrated significant results with its technology against pancreatic cancer, and GEDi Cube, with an AI, machine learning technology that has validated earlier diagnoses of lung cancer in humans, already expanding to 12 additional cancers, combining the companies is being seen as pointing to the future of medicine.

The technology multiplier effect of combining powerful advanced AI processing and machine learning capabilities, and proven leading-edge immunotherapy technology, lifts the fight against cancer to a new level. The success that both companies have shown with their innovative developments is expected to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

August 23, 2023 11:57:30
  • For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company’s marketing mix
  • The company’s marketing partner, Santen, has commenced the required registrational trial for UPNEEQ(R) in Japan and plans to begin the same in China in 2023
  • UPNEEQ(R) has strong U.S. intellectual property protection, with patents extending to 2039
  • RVL Pharmaceuticals launched its prescription ecommerce platform, Elevate, in July 2023, allowing providers and patients to purchase RVL products and sign up for auto-refills
  • UPNEEQ(R) consumer awareness remains very low among U.S. adult women, presenting a major opportunity to increase awareness and demand through Direct-to-Consumer efforts

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is available by prescription for the treatment of acquired blepharoptosis, or low-lying eyelid(s), in adults.

UPNEEQ(R) (RVL-1201) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (FDA) for acquired blepharoptosis. The company received FDA approval in July 2020 and launched UPNEEQ(R) in September 2020 to a limited number of eye care professionals, with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) CFO Featured in Proactive Interview

August 23, 2023 11:57:05

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, was featured in a recent interview with Proactive Investors that covers the company’s second-quarter performance and milestone achievement in setting a new record for shipments of its LiDAR technology, demonstrating its robust momentum in automotive and smart infrastructure sectors. Cepton CFO Hull Xu joined Steve Darling from Proactive to discuss the notable achievement of Cepton, pointing out that the company is poised for a substantial increase in shipment volume in each successive quarter throughout the remainder of the year. He also shared details on Cepton’s active fulfillment of a multi-million tolling contract, which underscores the company’s strong standing in the market. Cepton is on track to meet orders to support original equipment manufacturers’ (“OEM”) start of production by year-end and has successfully delivered to General Motors with support from Koito, a strategic partner. Xu additionally provided insights into Cepton’s Smart Infrastructure division. The company has secured its first production orders for lidar installations in multiple airports throughout the U.S.

To view the full press release, visit https://ibn.fm/66Yu7

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart citiessmart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

Genprex (NASDAQ: GNPX) Appoints Regulatory Expert as It Drives Clinical Programs Forward

August 23, 2023 11:56:34

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its appointment of Suzanne Thornton-Jones, Ph.D. as senior vice president, regulatory affairs. Dr. Thornton-Jones will leverage her expertise to guide Genprex’s regulatory submissions and strategy for its pipeline of gene therapy drug candidates. “We are delighted to welcome Dr. Thornton-Jones to the Genprex team as her strategic regulatory and drug development expertise, including with novel gene therapy products, will be invaluable as we advance our innovative gene therapies to treat cancer and diabetes,” said Rodney Varner, chairman, president and CEO at Genprex. “We look forward to benefitting from Dr. Thornton-Jones’ deep domain experience at this important point in Genprex’s growth, particularly as we advance and expand our clinical development programs in oncology with our REQORSA(R) Immunogene Therapy drug candidate and progress the development of our diabetes gene therapy program toward first-in-human studies. We look forward to Dr. Thornton-Jones’ guidance as we drive these important clinical programs forward.”

To view the full press release, visit https://ibn.fm/LV3VA

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The company’s lead product candidate, REQORSA(R) (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Each of Genprex’s three lung cancer clinical programs have received a Fast Track Designation from the Food and Drug Administration (“FDA”), and its SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

D-Wave Quantum (NYSE: QBTS) Announces Updates to Quantum Hybrid Solver

August 23, 2023 11:55:44

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, has updated its Constrained Quadratic Model (“CQM”) hybrid solver in its Leap(TM) quantum cloud service. According to the announcement, the enhanced Constrained Quadratic Model solver helps businesses solve more complex optimization problems through quantum/classical computation. First made available in October 2021, the CQM solver allows users to benefit from a simplified expression of their constrained problems. It expands the size and complexity of problems customers can solve with constraints in D-Wave’s hybrid solver to find the best answers to complex business problems. The updates announced today deliver increased performance for existing binary problem classes, which can include offer allocation, portfolio optimization, and satisfiability.

The updates deliver increased performance for existing binary problem classes, which can include offer allocation, portfolio optimization, and satisfiability. “Our mission at D-Wave is to unlock the power of practical quantum computing for our customers,” said D-Wave Quantum VP of software, algorithms and cloud services Trevor Lanting in the press release. “These most recent updates to our CQM hybrid solver reflect our commitment to building solutions that bring real enterprise applicability and impact today. We’re excited by the performance enhancements that we are seeing, and our rapid pace of innovation allows us to expand quantum-hybrid workflows to help solve increasingly complex problems.”

To view the full press release, visit https://ibn.fm/MO23s

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.DWaveSys.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Lexaria Bioscience (NASDAQ: LEXX) Affirms Product Superiority in 2023 Human Oral Nicotine Study

August 22, 2023 11:38:30
  • Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives
  • The study, which involved 36 participants, embraced a randomized, double-blind, cross-over study design
  • It also affirmed Lexaria’s product superiority while also showing DehydraTECH’s potential

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released results from its 2023 human oral nicotine study NIC-H22-1. Of note was its patented DehydraTECH(TM)–nicotine tobacco-free pouch product superiority, particularly when pitted against world-leading brands ZYN(R) and on!(R). The study proved that Lexaria’s product was statistically significantly faster than the two alternatives in the median time required to reach comparable maximum nicotine concentrations (“Tmax”) levels (https://cnw.fm/17JMQ).

Lexaria’s CEO, Chris Bunka, lauded his team for this achievement, especially considering they had to work without as many resources as global multi-billion-dollar behemoths. He also lauded the company’s…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

IGC Pharma (NYSE American: IGC) Announces Results of Annual Meeting

August 22, 2023 11:38:04

IGC Pharma (NYSE American: IGC) has announced that during its annual meeting of stockholders scheduled for and convened on Aug. 18, 2023, (the “annual meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 26, 2023, were passed by the requisite vote of the stockholders. Only stockholders of record as of the record date of June 21, 2023, were requested to and entitled to vote at the annual meeting. The press release outlines all proposals approved by the requisite vote of the stockholders, which include the election of Claudia Grimaldi to the company’s board of directors to serve as Class A directors until the 2026 annual meeting of stockholders and the proposal to ratify Manohar Chowdhry & Associates as the company’s independent registered public accounting firm for the 2024 fiscal year.

To view the full press release, visit https://ibn.fm/UwFid

About IGC Pharma Inc.

IGC Pharma develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps (“dysmenorrhea”), premenstrual syndrome (“PMS”), and chronic pain. IGC has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”) based formulation that is currently in a 146-person phase 2 clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). IGC also markets a wellness brand, Holief(TM), that targets women experiencing premenstrual syndrome and menstrual cramps.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Renovaro BioSciences (NASDAQ: RENB) Congratulates GEDi Cube on CMO Appointment

August 22, 2023 11:37:33

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, on Aug. 9 announced an exclusive, binding letter of intent with GEDi Cube. Today Renovaro BioSciences congratulated GEDi Cube on its appointment of Dr. Lester Russell as its chief medical officer. “We are excited about the appointment of Dr. Russell,” said Dr. Mark Dybul, CEO of Renovaro BioSciences. “As a seasoned expert in clinical medicine and digital health, he could enhance the capabilities of GEDi Cube to make a difference in the lives of people at risk of or suffering from serious illnesses.”

To view the full press release, visit https://ibn.fm/9CMOu

About Renovaro BioSciences Inc.

Renovaro BioSciences, formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as human immunodeficiency virus (“HIV”) and hepatitis B virus (“HBV”) infection. For more information, visit the company’s website at https://enochianbio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

D-Wave Quantum (NYSE: QBTS), Davidson Technologies Collaborate to Advance Intelligent Solutions for Defense and Aerospace

August 22, 2023 11:37:07

D-Wave (NYSE: QBTS), a leader in commercial quantum computing systems, software and services, has announced progress in a collaboration with Davidson Technologies, a technology services company that provides innovative engineering, technical and management solutions for the Department of Defense, aerospace and commercial customers. According to the update, the collaboration aims to create solutions that advance national defense efforts. At the Space and Missile Defense Symposium, the companies revealed their efforts in building two applications that focus on interceptor assignment and optimized radar scheduling.

For more information, visit https://ibn.fm/nlRyL

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Fintech Ecosystem Development (NASDAQ: FEXD) Eyes Leveraging Emerging Tech to Reduce Costs, Accelerate Money Transfers

August 21, 2023 11:31:22

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a company working to develop a global financial technology ecosystem comprising a network of mobile money platforms, technologies, applications, products, and services. “The technologies, the company’s website states, are meant to ‘make it easy to move money across borders to almost any place in the world, in virtually any currency, using your mobile phone or laptop.’ FEXD aims to use emerging technologies such as blockchain, web 3.0, artificial intelligence (“AI”), and the metaverse to reduce costs and accelerate the processing of money transfers, loans and other lifestyle services, which will benefit consumers and businesses in many countries, according to Dr. Sainful Khandaker, CEO, president and founder of FEXD,” a recent article reads. “With a goal of leveraging the power of such emerging technologies to benefit businesses and consumers downstream, FEXD is not only developing platforms and applications that support cashless transactions but also seeking to acquire and merge with high-growth global fintech companies primarily operating in South Asia with a high volume of customers and extensive network of agents.”

To view the full article, visit https://ibn.fm/XQZqy

About Fintech Ecosystem Development Corp.

Fintech Ecosystem Development is a special purpose acquisition company formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector. The company is sponsored by Revofast LLC and the management team led by CEO, president and founder Dr. Saiful Khandaker and a group of experienced fintech business and technology innovators. For more information about the company, please visit www.FintechEcosys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Announces Milestone: First EV Mullen THREE Truck Off Assembly Line

August 21, 2023 11:30:16

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has reached a milestone: the company’s first production vehicle, the Mullen THREE, has rolled off the assembly line. The Class 3 EV truck is being manufactured at Mullen’s commercial vehicle assembly facility located in Tunica, Mississippi. According to the announcement, the company anticipates increasing the production rate of the Mullen THREE as the year progresses. The company noted that when full production has been achieved, Class 3 production at its Tunica facility should reach 3,000 vehicles annually per shift. Mullen plans to add a second shift for Class 3 production once EV adoption rates increase, bringing total production capacity to 6,000 vehicles per year. Mullen’s strategic production plan also includes the production testing and launch of the Mullen ONE, its Class 1 EV Cargo Van; the manufacture of this vehicle will also take place in Tunica, with deliveries on customer orders for both commercial Class 1 and Class 3 vehicles expected by year end. According to the company, Mullen has received $79 million in purchase orders for the Mullen THREE, Class 3 EV trucks. The company’s Tunica facility is more than 120,000 square feet, is situated on more than 100 acres, and is near major rail lines, interstates, Mississippi river systems, and air logistics. “We have been true to our commercial Class 3 vehicle production commitments and have now achieved a significant milestone with the first trucks rolling off the line,” said Mullen Automotive CEO and chair David Michery in the press release.

To view a video of the event, visit https://ibn.fm/GJkRJ

To view the full press release, visit https://ibn.fm/laEBs

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Renovaro BioSciences (NASDAQ: RENB) CEO Discusses Product Development in Letter to Shareholders

August 18, 2023 11:13:04

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), earlier this year issued a letter to shareholders from its CEO Mark Dybul, MD, in which Dr. Dybul discussed scientific and product development advances and plans for the future. The advances included independently conducted studies that showed remarkably promising results, demonstrating and confirming proof-of-concept for the company’s cell-gene-immunotherapy for pancreatic cancer and, potentially, other solid tumors, as well as the accelerated timeline for submission of the company’s Pre-Investigational New Drug (“Pre-IND”) application to the U.S. FDA. “Despite significant challenges that would have derailed many companies, our strategic plan to focus on our most promising platform has allowed us to significantly de-risk our cancer immune oncology program and be in a strong position now. We have made substantial scientific and product development advances over the past 10 months. This was accomplished while substantially reducing operating costs – including, at my request, a decrease in my compensation as CEO – towards maximizing shareholder value,” Dr. Dybul wrote in the letter. “The progress with a platform that has key attributes that could potentially be leveraged for products to treat solid tumors, HIV and, perhaps, other infectious diseases is particularly encouraging.”

To view the full press release, visit https://ibn.fm/WALID

About Renovaro BioSciences Inc.

Renovaro BioSciences, formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as human immunodeficiency virus (“HIV”) and hepatitis B virus (“HBV”) infection. For more information, visit the company’s website at https://enochianbio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope, Inc. (NASDAQ: KSCP) K5 ASRs to Deploy with Major Self-Storage Platform

August 18, 2023 11:12:23

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced a new contract with a self-storage company for an initial order of five K5 ASRs. According to the update, the client is one of the fastest-growing self-storage platforms in the United States with assets located primarily in high-density, urban markets.

The announcement reads, “Knightscope’s K5 ASRs will patrol five storage locations – two in the Portland area and three others in California – to help mitigate risk and elevate the protection offered to tenants and their belongings. In addition to their security duties, the robots will broadcast helpful messages to passersby and act as brand ambassadors. Based on the success of these initial deployments, the client will be considering deployments at many other store locations.”

To view the full press release, visit https://ibn.fm/Vs4qY

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

BiondVax Pharmaceuticals (NASDAQ: BVXV) Advances NanoAb as IL-17 Drug Candidate for Psoriasis

August 18, 2023 11:12:04
  • Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs
  • BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better binding, and a higher level of stability at room temperature
  • Apogee recently went public at $500 million pre-money, raising $300 million in an upsized deal, and has a $1 billion market cap – should be an eye-opener to BiondVax investors who recognize benefits of NanoAbs over mAb development
  • The global psoriasis treatment market was valued at $26.13 billion in 2022 and is anticipated to reach $57.84 billion by 2031, growing at a CAGR of 9.23%

Modern-day medicine has been revolutionized and personalized to cater to more specific disease characteristics. A prime example of this innovation is monoclonal antibodies (“mAbs”) and nanosized antibodies (NanoAbs), therapeutic options that address diseases in ways other therapies cannot. Several companies are penetrating the market and a compelling comparison can be made between two – one supporting mAbs and the other NanoAbs. Both companies share similar objectives and stages of development.

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is focused on the development of NanoAbs derived from…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Fintech Ecosystem Development (NASDAQ: FEXD) Driving Digital Financial Inclusion on Power of AI

August 18, 2023 11:11:24
  • FEXD is developing a global financial technology ecosystem that will address unmet mobile money needs in developing and industrialized markets and make it easier and more affordable to transact digitally
  • The company aims to use emerging technologies such as AI to reduce costs associated with and fast-track the processing of money transfers and loans
  • AI is a powerful technology that has been positively associated with the improvement in digital financial inclusion
  • The technology is used in credit risk assessment, investment-related decision-making, fraud detection and prevention, prediction, and customer service
  • With FEXD eying digital money transfers, which are unfortunately prone to cyber threats and fraud attempts, the company aims to tap into the power of AI to promote security and efficiency, thus driving digital financial inclusion

Long before large language models (“LLMs”) like ChatGPT and Bard democratized artificial intelligence (“AI”), this powerful technology existed and was deployed in different industries. The banking, financial services, and insurance (“BFSI”) industry, for instance, is recognized as one of the earliest and most prominent adopters of the technology, having first incorporated some form of AI about three and a half decades ago (https://ibn.fm/wZMQi). But the rise of new frontiers in AI, such as generative AI, of which LLMs are part, has created new opportunities that incumbents and startups can use to their benefit.

The earliest implementation of AI in the BFSI space was in the domain of credit risk assessment. And many years on, financial services companies such as banks and lenders still use the technology to assess the creditworthiness of customers. But, compared to the formative years, AI has evolved, thanks in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

Cepton (NASDAQ: CPTN) VP of Product Talks Record LiDAR Shipments, Q2 Earnings

August 18, 2023 11:10:40

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, along with its Q2 performance and strategic developments are in the spotlight during a recent Proactive Investors interview. During the interview with Proactive’s Steve Darling, Cepton vice president of product Brunno Moretti provided an overview of the company’s second-quarter performance as well as key operational highlights. Moretti noted that Cepton has achieved a new company record for shipments of LiDAR technology across the automotive and smart infrastructure markets, which indicated the company’s upward momentum; Moretti also explained that the company is projecting a significant increase in shipment volume for each subsequent quarter throughout the remainder of the year and is actively fulfilling a multimillion-dollar tolling contract, which he called “a significant achievement” within Cepton’s portfolio. The two also discussed Cepton’s strategic expansion, particularly in Detroit, where the company has strengthened its team by adding industry expert Luis Gonçalves, formerly associated with General Motors and a veteran in the American automotive sector. “This move is expected to support Cepton’s volume production operations and enhance its market presence,” the announcement stated. “Cepton’s strong 2Q performance, strategic partnerships and expansion efforts underscore its commitment to advancing lidar technology and its applications in the automotive and smart infrastructure sectors.”

To view the Proactive interview, visit https://ibn.fm/7Ibtk

To view the full press release, visit https://ibn.fm/36Yjk

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D-perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors Business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about this company, please visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

RVL Pharmaceuticals (NASDAQ: RVLP) Spotlighted in Cantor Fitzgerald Research Brief

August 18, 2023 11:09:31

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, is featured in a recent Cantor Fitzgerald research brief. Noting that the stock “looks even more interesting post solid quarter and ahead of potential strategic acquisition,” the research brief reiterated its previous Overweight (“OW”) rating and 12-month price target of $6 for RVL Pharmaceutical shares, stating that RVLP’s commercial opportunities continue to be underappreciated and that upward earnings estimate revisions should drive the stock higher. The brief noted that RVLP’s prescription eye drop, UPNEEQ 0.1%, had been selected the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty annual beauty awards, and that the company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden RVLP’s portfolio and leverage the field force investment.

“RVLP said it is in advanced discussions with certain companies that it could potentially partner with or acquire to support growth and integrate into its infrastructure with meaningful synergies,” stated the Cantor Fitzgerald report. “RVLP [also] reported second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, year over year, respectively. RVLP highlighted its lower baseline of operating expenses. It streamlined its operating expenses to extend its cash runway, optimize its marketing mix and support strategic business development. This streamlining had a modest unfavorable impact on sales during the quarter. And at 6/30/23, the company had cash and cash equivalents of $19.2 million and senior secured indebtedness with aggregate principal maturities of $70.7 million.”

To view the full press release, visit https://ibn.fm/r81W9

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first nonsurgical treatment option approved by the FDA for acquired blepharoptosis. For additional information about this company, please visit www.RVLPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

SuperCom (NASDAQ: SPCB) Announces ‘Milestone’ Multimillion-Dollar Electronic Monitoring Contract

August 18, 2023 11:07:12

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, Internet of Things (“IoT”) and cybersecurity sectors, has secured a new contract to provide alcohol monitoring technologies and services in California. The contract, which is for an initial three-year term and is valued at up to $3 million, was secured through SPCB’s wholly owned subsidiary Leaders in Community Alternatives (“LCA”). Noting that the contract further solidifies the company’s strong position in the electronic monitoring industry, SuperCom called the contract win another milestone for the company’s expansion into the U.S. market. According to the announcement, the contract is already in effect, running through 2026 with potential for extensions and recurring revenue.

“Our reputation for providing reliable and high-quality electronic monitoring services was pivotal in securing the contract,” said SuperCom president and CEO Ordan Trabelsi in the press release. “This contract marks another strong achievement, building on our track record of securing numerous new electronic monitoring contracts in the United States and Europe. We are proud to have been chosen once again to support California’s criminal justice system. Our long-standing relationships with county customers and law enforcement underscores their trust in our technology and services. As we move forward, we remain committed to fostering strong partnerships, driving technological advancements, and delivering top-tier solutions that address the unique challenges faced by the criminal justice system. With a focus on technology innovation and global expansion, SuperCom is well-positioned to help lead the electronic monitoring industry into the future.”

To view the full press release, visit https://ibn.fm/CwqlU

About SuperCom Ltd.

Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification, and security solutions to governments and organizations, both private and public, worldwide. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secure multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one, field-proven Radio Frequency Identification (“RFID”) and mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation. For additional information about this company, please visit www.SuperCom.com

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Mullen Automotive (NASDAQ: MULN) Announces Commencement of Stock Buyback Program

August 18, 2023 11:06:42

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced the start of the company’s $25 million stock buyback program with the repurchase of 3.7 million shares of common stock for an aggregate of $3,626,000. The buyback program started on Aug. 16, 2023, and can continue through Dec. 31, 2023. Mullen’s chairman and CEO David Michery also purchased 102,040 shares in the open market on Aug. 16, 2023, at a price of $0.9842 per share. The company is committed to taking all available measures to regain compliance with the NASDAQ minimum $1.00 bid price requirement. “We believe that our stock is undervalued,” Michery was quoted in the press release. “The company has begun production of our Class 3 EV with deliveries pending to customers and a strong balance sheet allowing us to execute on our business plan.”

To view the full news release, visit https://ibn.fm/5lvRZ

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

RVL Pharmaceuticals (NASDAQ: RVLP) Enters Agreements for $5M Registered Direct Offering

August 17, 2023 10:44:22

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has entered into definitive agreements. The offering is expected to close on or about Aug. 18, 2023, and will be subject to customary closing conditions. The company anticipates gross proceeds from the registered direct offering to total approximately $5 million; RVL Pharmaceuticals plans to use the funds for general corporate purposes. The registered direct offering agreements are for the purchase and sale of 11,870,846 of RVLP ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.4212 per share. According to the announcement, the company also agreed to issue unregistered series A-1 warrants to purchase up to 11,870,846 ordinary shares and unregistered series A-2 warrants to purchase up to 11,870,846 ordinary shares to the investors.

The announcement stated that the exercise price for the series A-1 warrants is $0.4212 per share; the warrants will be exercisable on the effective date of shareholder approval of the issuance of the shares upon exercise of the series A-1 warrants and will expire five years after the date of shareholder approval. The exercise prices for the series A-2 warrants is $0.4212 per share; those warrants will be exercisable on the effective date of shareholder approval of the issuance of the shares upon exercise of the series A-2 warrants and will expire 18 months after the date of shareholder approval.

To view the full press release, visit https://ibn.fm/Ner5u

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first nonsurgical treatment option approved by the FDA for acquired blepharoptosis. For additional information about this company, please visit www.RVLPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

D-Wave Quantum (NYSE: QBTS) and Davidson Technologies Collaborate to Advance National Defense Efforts

August 17, 2023 10:41:39
  • D-Wave and Davidson revealed new joint applications focused on interceptor assignment and optimized radar scheduling at the recent Space and Missile Defense Symposium
  • The companies are working together to advance intelligent technology solutions for the defense and aerospace industries, creating applications that could support a variety of mission objectives

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, has announced that progress has been made in a collaboration with Davidson Technologies, Inc., a technology services company that provides innovative engineering, technical, and management solutions for the Department of Defense, aerospace, and commercial customers. The collaboration between D-Wave and Davidson is intended to create solutions that advance national defense efforts. Both companies were present at the Space and Missile Defense Symposium, revealing that together, they have built two applications – focusing on interceptor assignment and optimized radar scheduling (https://ibn.fm/XU9oE).

The interceptor assignment application is designed to mitigate potential attacks and can take into account multiple complex variables. These include missile capability in negating threats, a balanced allocation of missiles to threats, and the availability of resources to help quickly identify potential…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the collaboration between D-Wave and Davidson and the results thereof. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; D-Wave’s ability to expand D-Wave’s customer base and the customer adoption of D-Wave’s solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of D-Wave’s products; the effects of competition on D-Wave’s business; the risk that we will need to raise additional capital to execute D-Wave’s business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect D-Wave’s intellectual property; volatility in the price of D-Wave’s securities; the risk that D-Wave’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Knightscope, Inc. (NASDAQ: KSCP) Provides Q2 Update Video, Announces New ASR Deployment

August 16, 2023 11:27:38

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has released its Second Quarter 2023 Town Hall Update video. The company recorded its Aug. 14, 2023, town hall event; the video is available on the company website for those who were unable to attend the gathering in person.

In addition, the company announced the latest deployment of its ASR security solutions. According to the announcement, a K5 ASR has been deployed in North Carolina by KSCP reseller Weatherspoon Enterprises, Inc., a North Carolina-based integrated security services and solutions provider. Weatherspoon offers the ASR as part of its consulting and security services, which include the most cutting-edge technologies focused on public safety. Weatherspoon deployed the ARS to one of its customers in the state.

“Weatherspoon’s CEO, Charles Witherspoon, is an award-winning, 38-year law enforcement and Army veteran with a distinguished career developing and overseeing threat assessments, counterintelligence to terrorism, and responding to active shooter situations, as well as securing large-scale venues, buildings and assets,” Knightscope stated in the press release. “He and the Weatherspoon team are well-positioned to deploy Knightscope’s ASRs in a manner that bridges the best of both worlds — the response capabilities of human guards and the automated, real-time intelligence gathering of robots — to provide a complete and unparalleled safety package.”

In addition, Knightscope announced that its Robot Roadshow is slated to land in Dallas on Sept. 11–13, 2023. The roadshow will be part of the Global Security Exchange (“GSX”) 2023 conference and will be located outside the main entrance of the convention center. GSX is hosted by ASIS International, the world’s largest membership organization for security management professionals.

The event is designed to support the administration of essential industry certifications, standards and guidelines and offers an ideal setting for security professionals to stay informed, connected and prepared. GSX spotlights the industry’s latest technologies, making it the perfect place for Knightscope’s Robot Roadshow. The roadshow is an engaging experiential event that offers potential clients and the general public an opportunity to personally experience Knightscope solutions for protecting the places people live, work, study and visit.

To view the town hall video, visit https://ibn.fm/6o5kd

To participate in the Robot Roadshow, visit https://ibn.fm/NLvFs

To view the full press release, visit https://ibn.fm/73Ch1

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

Renovaro BioSciences (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

August 16, 2023 11:27:14

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent for its oncology platform, as well as promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. Scientists at the Fred Hutchinson Cancer Center were also, at that time, conducting studies of the company’s HIV platform with expected positive results. “We continue to prioritize the efficient research, development and commercialization of our promising oncology and HIV pipelines,” said the company’s CEO Dr. Mark Dybul. “Enochian’s future is bright, and we look forward to advancing potentially curative therapies for some of the world’s deadliest diseases.”

To view the full press release, visit https://ibn.fm/31reC

About Renovaro BioSciences Inc.

Renovaro BioSciences, formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as human immunodeficiency virus (“HIV”) and hepatitis B virus (“HBV”) infection. For more information, visit the company’s website at https://enochianbio.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BiondVax Pharmaceuticals (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

August 16, 2023 11:26:44

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis titled the report “Good Things Coming” and gave BVXV a Buy rating. The research report noted that BiondVax has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies, called NanoAbs, targeting Interleukin-17 (“IL-17”), specifically for the treatment of psoriasis and psoriatic arthritis. The agreement is with the Max Planck Society and the University Medical Center Gottingen (“UMG”) and is part of an ongoing collaboration BVXV has going with those two entities. According to the report, Max Planck and UMC Gottingen have already generated 11 potential therapeutic candidates. The report noted that the next step for BiondVax is to identify the best two or three of the potential candidates and begin preclinical in vivo proof-of-concept testing and toxicology studies; this would be in preparation for phase 1/2a clinical testing.

“We believe that BiondVax and its collaborators can move quickly, completing the in vivo studies by IH2024 and potentially starting phase 1/2a in 2H2024,” the report stated. “We see the plaque psoriasis market as an excellent opportunity for BiondVax. It’s target, IL-17, is already proven to be effective on even the most severe cases of plaque psoriasis. The NanoAb technology could enable BiondVax to develop an IL-17therapy that is deliverable in a localized manner to psoriatic plaques with the subsequent potential to significantly improve the toxicity profile over systemic IL-17, as well as to provide a novel way to expand the IL-17 market from only severe patients (about 10%–20% of the patient population) to mild and moderate patients (about 80% of the market). If the phase 1 data is positive, which we see as likely, significant interest from big pharma competitors already in the psoriasis market could be expected. . . . We are excited by the direction that BiondVax is taking its unique nanoantibody platform technology. We reiterate our Buy recommendation and $70 price target.”

To view the full report, visit https://ibn.fm/ZkrFF

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Unveils Ultra-High-Performance FIVE RS Crossover

August 16, 2023 11:26:20

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, announced its newest mode: the ultra-high-performance Mullen FIVE RS EV Crossover. According to the announcement, the newest addition to MULN’s offerings features a top speed of more than 200 mph and can accelerate from 0–60 mph in under two seconds. The FIVE RS is equipped with 800-volt architecture, all-wheel drive, a two-speed gearbox and more than 1,100 horsepower. MULN is planning to showcase the model at this season’s kickoff of its Strikingly Different EV tour, which begins on Aug. 20, 2023, in Austin, Texas. The company noted that because of the model’s high-powered capabilities, consumers will not be allowed to test drive the vehicle directly. Instead, potential buyers can ride in the Mullen FIVE RS alongside a professional race car driver, providing an up-close and personal experience in one of the fastest vehicles available. “I want to encourage shareholders to continue sharing thoughts and opinions with Mullen, and remember we are working together to achieve great things, including pushing the boundaries of EV performance and electrifying the world,” said Mullen Automotive CEO and chair David Michery in the press release.

To view the full press release, visit https://ibn.fm/BJptP

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

August 15, 2023 11:13:46
  • In June 2023, Renovaro announced that a potential IND application for its innovative cancer platform is on track for early 2024 FDA submission
  • The company in March 2023 announced proof-of-concept for its proprietary technology to treat pancreatic tumors
  • In August 2023, Renovaro announced its entry into a Letter of Intent to merge with GEDi Cube International Ltd. with the aim of accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases
  • As of August 2023, Renovaro has raised total cash of $82.7 million
  • The company’s IP portfolio covering gene and gene-modified cell therapies includes patents, patent applications and licensed technologies under patent application

Renovaro BioSciences (NASDAQ: RENB) formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (“HIV”) and Hepatitis B Virus (“HBV”) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BiondVax Pharmaceuticals’ (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics

August 15, 2023 11:13:25
  • Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies
  • The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030
  • The monoclonal antibodies market was valued at $210.06 billion in 2022, and it is expected to reach $494.53 billion by 2030
  • The nanobody market was valued $237.1 million in 2021 and is expected reach a value of $1.07 billion by 2028
  • BiondVax is uniquely positioned to rapidly advance from R&D towards commercialization

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is planning a rapid development path that leverages the company’s expertise and capabilities in biological drug development and manufacturing. Using a platform of alpaca-derived nanobodies (NanoAbs), BiondVax is targeting large market disorders underserved by current therapeutics, including COVID-19, asthma, and psoriasis. BiondVax’s diverse and growing pipeline is being developed in collaboration with the world renowned Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) in Germany.

The biologics market, which is comprised of any pharmaceutical drug product manufactured in, extracted from, or semi-synthesized from biological sources, was valued at $366.5 billion in 2021 and is expected to grow at a CAGR of 7.15%, resulting in a value of $719.94 billion by 2030. The introduction of targeted…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) Announces Q2 2023 Results

August 15, 2023 11:13:00

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterated upcoming milestones. “We are approaching the most important milestone to date since we launched CNS Pharma. We are just a few months away from reporting topline results from our Berubicin potentially pivotal study interim analysis and, although we do not know what the data looks like at this time, we remain hopeful as we also approach full enrollment of the trial,” said John Climaco, CEO of CNS Pharmaceuticals. “Looking ahead, we remain focused on executing on all of our operational efforts and, importantly, taking our Berubicin trial for GBM across the finish line. We are poised for an exciting remainder of the year with significant milestones anticipated in the near term and look forward to optimizing our opportunities to build value for all shareholders in the near and long-term.”

In addition, the company announced the presentation of updated results from the on-going study evaluating Berubicin, CNS Pharmaceuticals’ novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a poster presentation at the 2023 SNO/ASCO CNS Cancer Conference, held Aug. 10-12, 2023, in San Francisco, California. The presentation is now available on the company’s website. “Berubicin has demonstrated its capability to be an innovative treatment in GBM that is safe and well tolerated, which has the potential to be a novel and effective therapy for this disease. Based on the results we’ve seen preclinically and in the clinic thus far, including these updated results from our on-going potentially pivotal study, we remain optimistic that Berubicin may provide a much needed clinical benefit for GBM patients,” said Sandra Silberman, MD, PhD, chief medical officer of CNS Pharmaceuticals. “We look forward to upcoming interim results that will evaluate Berubicin compared to the current standard of care (Lomustine) for second line therapy in this disease.”

To view the full press releases, visit https://ibn.fm/886z1 and https://ibn.fm/1dtGF

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2024 Financial Report

August 15, 2023 11:12:30

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer’s disease, period cramps (dysmenorrhea), premenstrual syndrome (“PMS”) and chronic pain, is reporting on its financial and business results for the first quarter of the 2024 fiscal year, the period ended June 30, 2023. Highlights of the report include a 161% increase in net revenue, which totaled approximately $555,000 compared to $212,000 in the same quarter of 2023; continued momentum in the development of IGC’s phase 3 manufacturing facility located on the West Coast; a $12 million line of credit obtained to support working capital needs primarily related to Alzheimer’s research; a $3 million stock purchase agreement with several investors to further strengthen working capital and support the progress of phase 2 trials for IGC-AD1 in Alzheimer’s; and a notice of allowance from Commissioner of Patents, Canada, for the company’s patent filing covering the use of cannabinoids in the treatment of seizures.

“Our first fiscal quarter of 2024 was highlighted by substantial progress in our efforts to advance our lead drug asset, IGC-AD1, through phase 2 clinical trials on Alzheimer’s,” said IGC Pharma CEO Ram Mukunda in the press release. “We currently have 10 trial sites in the United States and Canada. The potential success of IGC-AD1 in Alzheimer’s holds the promise of positioning the company at the forefront of medical advancement, equipped with a first-mover advantage in delivering a solution tailored to a pressing medical need. By addressing the unmet challenges related to agitation in Alzheimer’s patients, IGC-AD1 has the potential to redefine treatment approaches while presenting a unique opportunity to introduce a novel drug without associated black box warnings.”

To view the full press release, visit https://ibn.fm/iXmkO

About IGC Pharma Inc.

IGC Pharma (dba IGC) develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer’s disease, period cramps (dysmenorrhea), premenstrual syndrome (“PMS”) and chronic pain. IGC has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”)-based formulation that is currently in a 146-person phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief(TM), that targets women experiencing premenstrual syndrome and menstrual cramps. For more information, visit the company’s website at www.IGCInc.us.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) Continues Sales Momentum with Three New Contracts

August 15, 2023 11:12:01

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, is seeing consistent rising sales; the company just announced the signing of three more contracts. According to the announcement, Knightscope has inked security deals with a third-party logistics (“3PL”) provider in the Midwest; a Central-U.S. regional transit authority and a country club in the Northeast.

According to the announcement, the regional 3PL provider is a current KSCP customer that signed its first Knightscope contract last year. The company offers value-added services such as warehousing and distribution, packaging, assembly, and fulfillment and has facilities in eight different states. The original contract called for an ASR deployment in Louisville, Kentucky; the new contract has expanded ASR coverage to a major appliance manufacturing site, where the robot will be patrolling parking lots of a large distribution center to provide protection of employees and visitors.

In addition, Knightscope reported that its Verizon (NYSE: VZ) partner “brought the company an opportunity to test emergency communications along a public transportation authority bus route in Arkansas,” the press release stated. “The transit company services rural and urban residents over 110 square miles and its first K1 Blue Light E-Phone will be installed by a Knightscope reseller. If the test is deemed a success, there is a potential to add 50 more at bus stops citywide.”

The third contract is also with an existing Knightscope client that is expanding its services. Currently, the private golf club in Maryland has eight wireless “golf boxes,” which are discreet, low-profile, black wireless call boxes mounted to an ornate pedestal designed specifically for country club golf course applications where cell phones are forbidden. The new contract calls for Knightscope to provide full-service maintenance to these devices.

In addition, Knightscope announced that its popular Robot Roadshow will be in Pittsburg this week; the roadshow will be at the UPMC Mercy Hospital on Aug. 17–18, 2023, from 10 a.m. to 2 p.m. ET. “The Robot Roadshow is an engaging experiential event, allowing potential clients and the general public to participate in expert-led demonstrations in a climate controlled, space-age ‘pod’ where attendees may experience the self-driving, electric technologies that are already helping protect the places people live, work, study and visit from Hawaii to Texas to Pennsylvania,” the company stated in the press release. “Visitors will be able to interact directly with Autonomous Security Robots, test a blue light emergency phone, and see the Knightscope Security Operations Center (KSOC) user interface in action.”

To participate in the Robot Roadshow, visit https://ibn.fm/NLvFs

To view the full press release, visit https://ibn.fm/tGVsr

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

RVL Pharmaceuticals (NASDAQ: RVLP) Announces Q2 2023 Results

August 15, 2023 11:11:30

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company today announced financial results for the three months ended June 30, 2023, and provided an update on its business review. “During the past several months, we have focused on expense reduction to extend runway, optimize marketing mix, and support business development efforts. While this streamlining had a modest unfavorable impact on sales during the quarter, we have gained greater conviction that driving consumer awareness is the next lever that may unlock meaningful growth for UPNEEQ. Importantly, we have also compiled encouraging data around our large total addressable market, or TAM, and the exceptionally low level of consumer awareness for UPNEEQ,” said RVL’s Chief Executive Officer Brian Markison. “In addition, we have continued our strategic business review, and are in advanced discussions with certain companies that we could potentially partner with or acquire to support growth and integrate into our infrastructure with meaningful synergies.”

To view the full press release, visit https://ibn.fm/jtfYr

About RVL Pharmaceuticals plc

RVL Pharmaceuticals is a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis. For more information about the company, visit www.RVLPharma.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Mullen Automotive Inc. (NASDAQ: MULN) Announces Fiscal Q3 Results, Business Update

August 15, 2023 11:10:59

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced financial results for its fiscal third quarter for the three and nine months ended June 30, 2023, and provided recent business updates. Among the highlights, the company’s board of directors has authorized a stock buyback program, pursuant to which the company may, until Dec. 31, 2023, purchase up to $25 million in shares of its outstanding common stock. Mullen ended fiscal third quarter on June 30, 2023, with stockholders’ equity of $351.8 million, compared to $157.0 million on Sept 30, 2022, which represents a 124% increase. In addition, during the quarter ended June 30, 2023, Mullen successfully secured $100 million in funding from its Series D preferred stock investors, which completes all remaining investment obligations to the Series D holders. With this latest investment, the company’s cash and cash equivalents exceed $200 million as of July 3, 2023, bolstering its liquidity and supporting its move from prototype to production for commercial vehicles. “We are very proud to report Mullen’s move from prototype to production for our Class 3 commercial vehicle,” said Mullen’s CEO David Michery. “This milestone marks the next phase of our journey towards transforming the electric vehicle landscape and driving sustainable mobility solutions.”

To view the full news release, visit https://ibn.fm/DtjTV

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen Commercial Class 1 and 3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2023 Financial Report, Corporate Update

August 14, 2023 11:35:02

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, is reporting its financial and operational results for the second quarter ended June 30, 2023. Highlights of the report include the closing of a $25 million secondary offering and $1.5 million registered direct offering, resulting in gross proceeds for HeartBeam of $26.5 million; the announcement in the “Journal of American College of Cardiology: Advances” of a foundational study evaluating the ability of the company’s VECG technology platform to detect the presence of coronary artery occlusions; the addition of three members to the company’s board of directors along with the announcement of Deborah Castillo, PhD, as VP of regulatory affairs; receiving an automated cardiac detection patent from the United States Patent and Trademark Office for the AIMIGo(TM) System; and the submission of a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for version 1 of the HeartBeam AIMIGo System.

“The second quarter of 2023 was highlighted by continued progress and validation of our technologies, the publication of our first, and foundational, study demonstrating the ability of our VECG platform, and several key additions to the team,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “Our strategic focus is to enable timely delivery of our ambulatory VECG products, which are our key future value drivers. . . . We recently closed $26.5 million in common stock-only financings to fund operations into late 2024. Proceeds are being used to fund development and regulatory work for the HeartBeam AIMIGo VECG device and to ready the product for limited market release during the second half of 2024. The product and regulatory efforts include first obtaining an FDA 510(k) clearance for the HeartBeam AIMIGo VECG device. We submitted this application to the FDA in May. This will be followed by a second FDA application on the system’s ability to synthesize a 12L ECG. We look forward to providing updates on our progress in the months ahead.”

To view the full press release, visit https://ibn.fm/1pj6x

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the US Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Pushing AI Conversation Forward

August 14, 2023 11:34:42

Fintech Ecosystem Development Corp. (NASDAQ: FEXD), a special purpose acquisition company (“SPAC”), is exploring the use of artificial intelligence (“AI”) to power financial solutions. “As a company that understands the financial sector, FEXD knows the potential that artificial intelligence (‘AI’) has and the value it brings in transforming an industry that has, for a long time, arguably lacked innovation,” a recent article reads. “With a growing range of applications, from simple chatbots to credit risk management tools, AI is finding its way to the core of financial solutions, and all stakeholders welcome it. So far, JPMorgan Chase, critical among other players in its space, has reported leveraging AI for fraud detection for its account holders. As a showcase of what AI is capable of, the bank has been able to implement a proprietary algorithm that detects fraud patterns, earning it high scores in both security and reliability. This, along with other additional benefits, such as speeding up services, allowing financial institutions to make more informed risks, and creating avenues for better customer relationship management, point to the potential of AI in the financial space. By focusing on such, FEXD is pushing the AI conversation forward while exploring ways to develop this technology further to address unmet mobile money needs in developing and industrialized countries and markets.”

To view the full article, visit https://ibn.fm/eKbRm

About Fintech Ecosystem Development Corp.

Fintech Ecosystem Development is a special purpose acquisition company formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector. The company is sponsored by Revofast LLC and the management team led by CEO, president and founder Dr. Saiful Khandaker and a group of experienced fintech business and technology innovators. For more information about the company, please visit www.FintechEcosys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) ‘Secret Agent Man’ Robot Security Guard Featured in Fox News Report

August 14, 2023 11:34:23

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has been spotlighted in a recent Fox News report. The Aug. 9, 2023, report noted that Crocker Park, an Ohio shopping center, is integrating cutting-edge AI tech by deploying a 400-pound robot security guard to further ensure safety. Crocker Park VP of marketing Stacie Schmidt called the Knightscope ASR a “secret agent man” (“SAM”), noting that the robot was the newest member of the mall’s security team.

Crocker Park is an open-air shopping mall in Westlake, Ohio, a suburban town located about 15 miles outside of Cleveland; the mall is owned by Stark Enterprises. An estimated 10 million people visit the mall every year. The site is also home to 1,000 residents living in luxury apartments. The robot, which patrols sidewalks and acts as a “watchdog” 24 hours a day, uses 360-degree video streaming and recording video capabilities to monitor specific areas and report any potential issues.

“Our priority has always been to provide a safe and secure environment for everyone who visits our center, and the Knightscope robot will play a crucial role in enhancing our existing security measures,” said Stark Enterprises vice president of security Sean Flanigan.

To view the full article, visit https://ibn.fm/E6try

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

BiondVax Pharmaceuticals (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

August 14, 2023 11:33:58

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its financial results for the second quarter ended June 30, 2023; the report also included a business update. Highlights of the report include R&D expenses for the quarter totaled $1.45 million compared with $1.97 million for the same period in 2022; marketing, general and administrative expenses for the quarter reached $1.14 million compared with $1.29 million for the 2022 period; total operating expenses for the quarter amounted to $2.56 million compared with $3.26 million for Q2 2022. The report also showed that financial (loss) income for Q2 totaled $1.16 million loss compared with $0.28 million income for the three months ended June 30, 2022, with net loss for the same period reaching $3.76 million compared with $2.98 million for same period in 2022. Business updates include the creation of a contract development and manufacturing organization (“CDMO”) in parallel to its innovative R&D business unit; the move is designed to leverage its aseptic manufacturing site and laboratories. In addition, the company signed an exclusive license agreement with Max Planck Innovation for development and commercialization of a novel anti-IL-17 NanoAb (VHH antibody) for treatment of autoimmune and inflammatory diseases including psoriasis, and the company is also pursuing a strategic partnership for its COVID-19, self-administered inhaled NanoAb therapeutic/prophylactic. The company also noted that NanoAbs for treatment of additional autoimmune diseases are being developed as part of a research collaboration with Max Planck and University Medical Center Göttingen.

To view the full press release, visit https://ibn.fm/jory3

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Freight Technologies (NASDAQ: FRGT) Monitoring Developments in Commercial Vehicles Industry

August 14, 2023 11:33:38

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company revolutionizing cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility and simplicity, is closely monitoring speed limiter directives on commercial vehicles. “As a company heavily invested in the industry, such directives could impact its performance and service delivery,” a recent article reads. “The Federal Motor Carrier Safety Administration (‘FMCSA’) proposed a rule that would mandate speed limiters for most commercial vehicles. While the exact speed has not been confirmed, safety groups have proposed a 60 mph limit for heavy-duty trucks. This is not the first time such a proposal has been brought forth. Back in the Obama administration, a similar suggestion was made, ultimately facing opposition from the American Trucking Association (‘ATA’)… The FMCSA has yet to communicate its decision on the matter, pending its review of over 15,000 comments. The ruling is projected to come in late summer or early fall, but FRGT is keeping a close eye on the matter and monitoring its development.”

To view the full article, visit https://ibn.fm/VGQRP

About Freight Technologies Inc.

Freight Technologies (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a B2B cross-border shipping marketplace in the USMCA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, please visit Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT         

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

D-Wave Quantum (NYSE: QBTS) Releases Q2 Financial Highlights, Business Updates

August 14, 2023 11:33:06

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services, is reporting on its financial results for fiscal second quarter ended June 30, 2023. Highlights of the report include $1.7 million in revenue, total bookings of $2.5 million, and a cash balance of more than $50 million. In addition, the company signed several new and expanded existing customer engagements with Forbes Global 2000 companies during the quarter, while also working with customers on a variety of new quantum and quantum-hybrid applications including media and advertising optimization, industrial construction, financial market performance predictions, transportation logistics and more. The company saw its fifth consecutive quarter of year-over-year growth in bookings as well as an increase in average deal size per booking.

“Our second quarter results reflect, we believe, growing enterprise commitment to and investment in practical quantum computing solutions that can address their complex operational challenges today,” said D-Wave CEO Dr. Alan Baratz in the press release. “Our triple-digit increases in bookings and average deal size on a year-over-year basis are evidence, in our opinion, of forward-looking organizations prioritizing quantum as part of their modern tech infrastructure. Companies and governments alike appear to be recognizing the value of today’s market-ready annealing quantum computing systems to drive business and national competitiveness. We’re helping harness the power of this transformative technology through industry-leading quantum hardware and software solutions and a consultative professional services approach that fuels application development and, increasingly, is preparing these applications for in-production scenarios that support customers’ daily operations.”

To view the full press release, visit https://ibn.fm/3NBBq

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.DWaveSys.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

SuperCom Ltd. (NASDAQ: SPCB) Is ‘One to Watch’

August 11, 2023 11:38:52
  • Trailing-Twelve-Month (“TTM”) Revenue increased by 106% YoY to $25.5 million from $12.4 million in the prior 12-month period, outpacing the global industry average by 10x
  • TTM EBITDA increased to $2.5 million from -($0.25) million in the prior 12-month period
  • The company’s Q2 2023 revenue increased by 141% YoY to $7.7 million
  • The company has seen a high YoY quarterly revenue growth trend: Q3 2022 – 102%; Q4 2022 – 69%; Q1 2023 – 109%
  • SuperCom’s recurring revenue represents 73% of total revenue
  • Approximately $200 million in EU contracts up for award in the upcoming 18 months
  • Over 65% win rate in national government tender in the EU
  • High entry barriers, requiring 5-10 years of specific industry experience, with only 10 global players
  • More than $40m invested in the research and development of the PureSecurity suite

SuperCom (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Mullen Automotive (NASDAQ: MULN) Commences Class 3 Vehicle Production at Tunica Facility

August 11, 2023 11:38:33

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced the start of vehicle production at its Tunica, Mississippi, assembly plant for the Mullen THREE, Class 3 EV truck with first customer deliveries on track to begin in August and September. According to the update, the company will be gradually ramping up the production rate over the course of September through December, with Class 3 production capacity at the Tunica facility currently planned for 3,000 Class 3 vehicles per year. To date, Mullen has received $79 million in purchase orders for 1,250 Mullen THREE, Class 3 EV trucks from Randy Marion Automotive Group and MGT Lease Company. “I am proud to announce that our Class 3 vehicle line is now in production mode at our Tunica facility,” said David Michery, CEO and chairman of Mullen Automotive. “Our team has been working seven days a week, day and night, getting this plant reconfigured and ready for Class 3 production.”

To view the full news release, visit https://ibn.fm/SHN0E

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Genprex (NASDAQ: GNPX) Granted FDA Orphan Drug Designation for REQORSA(R) for SCLC

August 11, 2023 11:37:49

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to the company’s lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (“SCLC”). In addition to ODD for the treatment of SCLC, in June 2023, the FDA granted Fast Track Designation (“FTD”) for REQORSA Immunogene Therapy, in combination with Genentech Inc.’s Tecentriq(R) in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. The FDA has also granted Genprex FTD for two other indications of REQORSA Immunogene Therapy, including REQORSA in combination with Tagrisso for non-small cell lung cancer (“NSCLC”) in patients who have progressed after Tagrisso treatment, and REQORSA in combination with Keytruda for NSCLC in patients who have progressed after Keytruda treatment. “We are excited to receive Orphan Drug Designation from the FDA for REQORSA for patients with SCLC,” said Rodney Varner, president, chairman and CEO at Genprex. “This FDA Orphan Drug Designation in combination with our recently received FDA Fast Track designation underscores the great need for better treatment options for patients with SCLC, ES-SCLC and NSCLC. We look forward to initiating the Acclaim-3 clinical trial expected in the fourth quarter of 2023 in order to bring hope of an effective new therapy to patients suffering with this life-limiting cancer.”

To view the full press release, visit https://ibn.fm/2lNPU

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The company’s lead product candidate, REQORSA(R) (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Each of Genprex’s three lung cancer clinical programs have received a Fast Track Designation from the Food and Drug Administration (“FDA”), and its SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Lexaria Bioscience (NASDAQ: LEXX) Reports Results from Human Oral Nicotine Study Evaluating DehydraTECH(TM)-Nicotine

August 10, 2023 11:14:33

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting results from its 2023 human oral nicotine study NIC-H22-1. The study compared Lexaria’s DehydraTECH(TM)-Nicotine tobacco-free pouch to two world-leading brands: ZYN(R) and on!(R) ZYN(R) is from Swedish Match and on! comes from Altria Group Inc. subsidiary Helix Innovations LLC. According to the report, DehydraTECH-Nicotine reached maximum blood saturation levels faster than either of the two other brands. In addition, superior subjective performance characteristics were observed in the study. Specifically, Lexaria’s oral nicotine pouch was significantly faster in the median time required to reach comparable maximum nicotine concentrations within the bloodstream than both on! and ZYN, 15% faster and 20.2% faster respectively. According to the announcement, the next step for the company is to seek to commercialize DehydraTECH-Nicotine with suitable industry partners based on its clinical and intellectual property advancements.

“With just five short years of R&D and product development, Lexaria has been able to develop an oral nicotine product that meets or exceeds the performance of the world’s leading existing brands,” said Lexaria Bioscience CEO Chris Bunka in the press release. “This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths. We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates advantages of DehydraTECH processed nicotine relative to the competitive landscape.”

To view the full press release, visit https://cnw.fm/nKBWn

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Knightscope, Inc. (NASDAQ: KSCP) Announces Second Deployment to Chicago

August 10, 2023 11:13:59

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, announced that one of its K5 ASRs is now patrolling the parking lot of a mixed-use facility in Chicago. The deployment, the latest in a growing number of contracts for the company, is with a property management group. The parking lot provides parking for both retail and professional tenants.

According to the company, this is the second deployment in the Windy City and is located in an area where crime, trespassing, vehicle break-ins, and catalytic converter thefts are rising. Knightscope’s ASRs support and enhances security personnel and operations already in place, providing a safer environment for local residents, employees and visitors. The company has provided a four-step plan for increasing security around high-value properties such as this urban development parking lot and has reported measurable success.

In addition, Knightscope has released new API access specifications for its security robot user interface. The new release “help clients collaborate and more easily integrate Knightscope’s advanced technology solutions with existing incident management systems,” the company states in the press release. “In order for security teams to work efficiently, it’s critical that these tools integrate seamlessly within organizational workflows. End-user organizations will now be able to more easily utilize disparate and previously siloed solutions, enabling them to elevate their threat detection, response and investigative capabilities.”

To view the full press release, visit https://ibn.fm/7gOp6

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) Deploys K1 Hemisphere ASRs for Hawaii-Based Evaluation Client

August 9, 2023 11:20:13

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced that it delivered on yet another important milestone in deploying its first two K1 Hemisphere ASRs at an undisclosed location in Hawaii for the final phase of product development – client testing. According to the update, Knightscope will collect insightful feedback over the next several weeks from its evaluation client, a global brand of full-service hotels and resorts, who will put the Hemisphere through its paces in a real operating environment. A number of pre-orders from various clients are due to be fulfilled thereafter.

William Santana Li, chairman and CEO, Knightscope, said of the deployment, “Criminals and terrorists can be anywhere. If we are to fulfill our mission, then Knightscope needs to be everywhere, both outdoors and indoors. Similar to our recently announced Automated Gunshot Detection (‘AGD’), this all-new product continues the march towards significantly increasing our TAM (‘total addressable market’) as the go-to public safety innovator.”

To view the full press release, visit https://ibn.fm/S3Va7

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Announces First Peer-Reviewed Publication Based on VECG Tech

August 9, 2023 11:19:46

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI. The company today announced the publication of a foundational study demonstrating the ability of its VECG platform to detect the presence of coronary artery blockages. The publication* appeared in JACC: Advances, a journal of the American College of Cardiology, and discussed how HeartBeam’s VECG technology detects the presence of a coronary occlusion, the cause of heart attacks, with the same accuracy as a standard 12-lead electrocardiogram (“12L ECG”). “This is the first peer-reviewed publication based on our novel VECG technology,” said Branislav Vajdic, Ph.D., CEO and founder of HeartBeam. “It demonstrates the potential for an easy-to-use, patient-held device to be employed in the detection of heart attacks at home. By combining the novel VECG approach with a system that incorporates a patient’s baseline signal, our technology was shown to have accuracy in detecting coronary occlusions similar or better to that of cardiologists evaluating a 12L ECG.”

To view the full press release, visit https://ibn.fm/m5TNX

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

*Shvilkin A, Vukajlović D, Bojović B, et al. Coronary Artery Occlusion Detection Using 3-Lead ECG System Suitable for Credit Card-Size Personal Device Integration. https://doi.org/10.1016/j.jacadv.2023.100454.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Renovaro BioSciences (NASDAQ: RENB), GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer

August 9, 2023 11:19:09

Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, and GEDi Cube Intl Ltd. have executed a binding, exclusive letter of intent (“LOI”). The LOI outlines the merge of a subsidiary with GEDi Cube, a cutting-edge health AI company. According to the announcement, the resulting company would focus on accelerating the diagnosis of cancer and other diseases, as well as enhancing treatment effectiveness, discovering new therapies and expanding access to life-saving technologies. According to the announcement, Renovaro Biosciences officials are confident that joining forces with GEDi Cube could “enhance the efficacy of upcoming trials and speed up the discovery of novel treatment approaches.” Renovaro is currently involved in studying pancreatic cancer and potential treatments; the company also plans to include other solid tumors with short life-expectancy in studies that are slated to start by mid-2024.

“I have been privileged to lead life sciences groups at Intel, Oracle and, most recently, NVIDIA,” said GEDi Cube International Ltd. CEO Craig Rhodes in the press release. “But GEDi Cube’s remarkably innovative technology developed over nearly a decade has already validated earlier diagnoses of lung cancer in humans at a leading university hospital and created the technology for 12 additional cancers, including pancreatic and breast cancer, which is very inspiring and exciting. We are rapidly expanding our technologies to include other cancers and diseases. I believe that uniting with Renovaro Biosciences’ potential solid tumor therapies is not merely synergistic. It could also create a multiplier effect to expedite diagnosis, improve treatment outcomes and discover, in silico, new therapies to improve many lives.”

To view the full press release, visit https://ibn.fm/hskUn

About Renovaro BioSciences Inc.

Renovaro BioSciences is an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company’s advanced cell, gene and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms. For more information about the company, visit www.RenovaroBio.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Freight Technologies (NASDAQ: FRGT) Helping Efficiently Move Commerce with Fr8App Solution

August 8, 2023 11:57:42

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a supply chain innovator, recently welcomed an extensive new pool of truck drivers working within the United States-Mexico-Canada Agreement (“USMCA”) trade area, expanding the reach of its platform and increasing the ability of commercial freight transportation networks to manage shipping loads of all sizes. “Fr8Tech recently announced completion of its collaboration with automated booking solutions platform Trucker Tools, integrating Trucker Tools’ extensive network of over 315,000 carriers across the United States with Fr8Tech’s load-matching solution Fr8App,” a recent article reads. “Fr8App streamlines the process of connecting shippers with carriers within the USMCA (formerly ‘NAFTA’), both domestically and across international borders, using artificial intelligence (‘AI’) and machine learning technology. Fr8App makes it simpler for businesses to post notice of their product load and destination needs, and for truck drivers to view and instantaneously bid on those available loads if the rate aligns with the target, helping the marketplace to efficiently move commerce with trucks filled to a maximum capacity. Fr8App and the suite of companion brands produced by Fr8Tech further empower shippers and carriers by helping them to easily track loads in real time as they are moving over the road, complete necessary documentation, find dedicated truck services, and transparently review truck operations, helping to eliminate costly errors.”

To view the full article, visit https://ibn.fm/j7T35

About Freight Technologies Inc.

Freight Technologies (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (“Fr8App”), is a B2B cross-border shipping marketplace in the USMCA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, please visit Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT         

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

Knightscope, Inc. (NASDAQ: KSCP) to Host 2Q Conference Call and Webcast

August 8, 2023 11:57:15

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced plans to hold its Second Quarter Town Hall Update to share current events and 2023 financial highlights following the filing of its 10-Q update with the U.S. Securities and Exchange Commission. The company’s CEO and Chairman William Santana Li will deliver a pre-recorded video update at the top of the meeting to cover Q2 2023 performance metrics followed by a live question-and-answer session with supporters, investors and analysts in an intimate online forum with no moderator.

The announcement reads, “The conference call / webcast will take place on Monday, Aug. 14, 2023, at 1 p.m. Pacific Time. Those interested in attending must RSVP at www.knightscope.com/rise. The pre-recorded portion of the Town Hall presentation, written transcript and supporting financial information will also be posted at the conclusion of the event at www.knightscope.com/rise.”

To view the full press release, visit https://ibn.fm/15IMv

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

Lexaria Bioscience (NASDAQ: LEXX) Celebrates ‘Strategically Important’ Patent Granted in US

August 8, 2023 11:56:56
  • Lexaria recently celebrated the receipt of its 35th overall granted patent worldwide when the USPTO recently awarded US patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine”
  • The company described the new patent as “strategically important”
  • The patent positions the company to tap into the growing oral nicotine market and offers protection in one of the world’s leading oral nicotine markets
  • This patent could also lead to additional subsequent patents from within this family
  • Lexaria’s DehydraTECH-nicotine formulation is patent granted for oral nicotine delivery in the US, Canada, and Australia

When Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced receipt of an Australian patent on March 8, 2022 (https://cnw.fm/41v9c), its resolve to continue expanding its intellectual property (“IP”), particularly within the oral nicotine sector, received a significant boost. The then-new Australian patent had expanded upon the company’s IP rights to apply its DehydraTECH(TM) technology platform to most oral forms of nicotine. Still, the company intended to continue growing its existing portfolio, expanding IP protection to multiple other jurisdictions.

Motivated, Lexaria filed a new patent application with the United States Patent and Trademark Office (“USPTO”) shortly thereafter on March 22. And, more than a year later, the application has proven successful, with the company recently celebrating the receipt of the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) Releases Q2 2023 Financial Report, Corporate Update

August 8, 2023 11:56:33

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, has released its financial and corporate report for the second quarter, the period ended June 30, 2023. Financial highlights of the report include a 9% increase in total revenue with revenue coming in at $2.8 million; gross margins of 16%, a company record; and product revenue reaching $2.8 million, a 92% increase. Second quarter 2023 GAAP net loss was $14.2 million, with non-GAAP net loss reaching $11.8 million and adjusted EBITDA totaling $(12.6) million. Business highlights for the quarter included record shipments of lidar units in both the automotive and smart infrastructure spaces; record shipment volume as Cepton continued fulfillment on a multimillion-dollar tolling contract, its largest contract to date; and increased interest from both consumer and commercial vehicle OEMs in lidar-enabled ADAS systems.

The company also completed the engineering validation of point cloud processing ASIC (Komodo) and shipped the initial units of Nova sensors featuring Komodo to its lead autonomous ground vehicle OEM customer while also designing and developing automated testing equipment for mass production quality control and developing enhanced calibration equipment. “We set new company records for shipment volumes across both automotive and smart infrastructure end markets during the second quarter,” said Cepton cofounder and CEO Jun Pei in the press release. “Our strong execution capabilities while maintaining our commitment to quality and reliability will be key differentiating factors as our shipments continue to grow for the remainder of this year to meet our OEM customer needs.”

To view the full press release, visit https://ibn.fm/umGk2

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D-perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors Business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about this company, please visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

CISO Global (NASDAQ: CISO) Launches Argo Edge Cloud Security Platform

August 8, 2023 11:56:15

CISO Global Inc. (NASDAQ: CISO), has unveiled Argo Edge, a powerful tool stack the company has been developing and testing for the past two years. According to the announcement, Argo Edge combines the most sought-after security technologies available with CISO’s proprietary IP and threat feeds to provide a prebuilt, easy-to-implement solution created for use by both government and privately held entities. The new AI-powered security solution, which has been independently valued at $49 million, enhances cybersecurity effectiveness through coordination, integration and automation. The company stated that Argo Edge layers together preconfigured, preintegrated technologies that include cloud firewall as a service (“FaaS”), secure internet gateway, secure authentication, secure service edge (“SSE”) and containerized internet browser sessions for each user. Argo Edge also provides Zero Trust Network Access (“ZTNA”), Cloud Access Security Broker (“CASB”) and Data Loss Protection (“DLP”) capabilities along with overall improved network performance.

“We believe this valuation solidifies CISO Global as a growing leader in the cybersecurity industry, and that the solution’s capabilities validate the company’s ability to deliver on its mission to demystify and accelerate its clients’ journey to cyber resilience,” said CISO Global CEO David Jemmett in the press release. “Unlike most security platforms currently on the market that add complexity and increase the need for additional staff to manage them, Argo Edge leverages automation and preconfigures highly complex security processes.”

To view the full press release, visit https://ibn.fm/Ui8jE

About CISO Global Inc.

CISO Global is an industry leader as a managed cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

D-Wave Quantum (NYSE: QBTS), Davidson Technologies Showcase National Defense Solutions

August 8, 2023 11:55:55

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services, is collaborating with Davidson Technologies Inc. to create innovative new solutions to complex problems in the defense and aerospace sectorsDavidson Technologies is a technology services company that provides innovative engineering, technical and management solutions for the Department of Defense, aerospace and commercial customers. The two companies are participating in this week’s Space and Missile Defense Symposium.  

According to the announcement, D-Wave and Davidson Technologies have built two new applications. The interceptor assignment app is designed to mitigate potential attacks by evaluating a multitude of complex variables, including missile capability in negating threats, balanced allocation of missiles to threats, and availability of resources to help quickly identify the potential defense threats and identify key mitigation tactics. The second application, focused on radar scheduling, manages the time-limited resources of a phased-array radar system, thereby enabling scheduling of communication with moving objects.

“By utilizing emerging and advanced technologies, Davidson is able to provide its customers with unique military implementation and national defense tools,” said D-Wave Quantum CEO Dr. Alan Baratz in the press release. “We share that spirit of imagining the unimaginable and harnessing the power of technology to keep America safer. We are excited to see advancement in our collaboration and look forward to more robust application development over our multi-year relationship.”

To view the full press release, visit https://ibn.fm/At6d3

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.DWaveSys.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Fintech Ecosystem Development (NASDAQ: FEXD) Equips Users with Scalable Access to Cashless Alternatives

August 7, 2023 12:44:16
  • FEXD understands the changing dynamics and the growing preference for digital payments
  • Through its aggressive yet strategic acquisition approach, FEXD is offering solutions that make it easy to move money across borders
  • By prioritizing developing nations and creating systems and infrastructure unique to the needs of customers in these countries, FEXD is addressing the issue of gross unmet mobile needs
  • This reflects the company’s commitment to its mission and to creating shareholder value

Fintech Ecosystem Development (NASDAQ: FEXD), a special purpose acquisition company (“SPAC”), is focused on the changing consumer landscape and how digital payments are shaping the way people transact. In response, the company is pushing for the creation and proliferation of much-needed scalable access to systems and infrastructure that facilitate cashless payments, ultimately playing an integral role in advancing a cashless society, both in the U.S. and around the world.

According to Pew Research, it was estimated that, in 2022, two-fifths of Americans used no cash. Additional studies showed that 11% of U.S. adults have stopped using cash, up from 5% five years ago, with the average number of cash payments falling from 26% in 2019 to 20% in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities

August 7, 2023 12:43:50

CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status as a cancer-fighting anthracycline that crosses the blood-brain barrier to attack central nervous system tumors directly. Berubicin also distinguished itself by presenting statistically significant improvement in nearly half of the two dozen patients evaluated in a phase I trial in 2006, including one patient whose last-known status remained cancer free as the current trial process began ahead of the COVID-19 pandemic,” a recent article reads. “CNS Pharmaceuticals has raised sufficient capital to enable the company to secure its trial beyond the interim analysis at least into the fourth quarter. Primary completion of the trial is expected next year, with final results in late 2024 or early 2025. The trial has achieved global status, recruiting patients in the United States, Spain, France, Switzerland and Italy.”

To view the full article, visit https://ibn.fm/onSyD

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Genprex’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential

August 7, 2023 12:43:31

Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. FDA Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combination with Tecentriq(R), a cancer immunotherapy treatment developed and sold by Genentech, Inc., in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. “The FTD is for the company’s Acclaim-3 patient population, and Genprex expects to initiate its Acclaim-3 clinical trial by enrolling the first patient in the third quarter of 2023… The company previously received two other FTDs. In 2020, Genprex announced that the FDA had granted FTD for its REQORSA therapy in combination with AstraZeneca’s (NASDAQ: AZN) Tagrisso(R) in patients with late-stage non-small cell lung cancer (‘NSCLC’) whose disease has progressed after treatment with Tagrisso. Later, in 2022, the company received its second FTD for REQORSA in combination with Merck & Co Inc.’s (NYSE: MRK) Keytruda(R) in patients whose disease progressed after treatment with Keytruda,” explains a recent article. “This is another exciting achievement in our REQORSA drug development program, which further validates REQORSA’s potential not only in NSCLC but also in SCLC. We look forward to accelerating the clinical development of REQORSA, and potentially providing a new treatment option for patients with SCLC,” Rodney Varner, chairman, president and CEO of Genprex, is quoted as saying.

To view the full article, visit https://ibn.fm/kcN1w

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The company’s lead product candidate, REQORSA(R) (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Each of Genprex’s three lung cancer clinical programs have received a Fast Track Designation from the Food and Drug Administration. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

D-Wave Quantum (NYSE: QBTS) Announces Collaboration with VINCI Energies and QuantumBasel

August 7, 2023 12:42:49
  • D-Wave, VINCI Energies, and QuantumBasel’s work will include using D-Wave’s annealing quantum computers and quantum hybrid solvers to create a series of quantum-hybrid applications
  • VINCI Energies is exploring the capabilities of quantum computing over classical computing methods for building heating, ventilation, and air conditioning (“HVAC”) system design
  • D-Wave’s Leap(TM) quantum cloud service delivers immediate, real-time access to the company’s Advantage(TM) Quantum Computer and quantum hybrid solver service, with enterprise-class performance and scalability

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, focused on delivering customer value via practical quantum applications, has announced a collaboration with QuantumBasel and VINCI Energies, an accelerator of environmental and digital transition, to explore quantum solutions for industrial construction. QuantumBasel and VINCI Energies will work on the research and development of a series of quantum-hybrid applications – which will use D-Wave’s annealing quantum computers and quantum hybrid solvers through the Leap(TM) quantum cloud service – to provide VINCI Energies with real-time access to quantum solutions.

“Construction projects feature a multitude of optimization challenges that can contribute to cost overruns and delayed building completions when not adequately addressed. We believe today’s quantum-hybrid technologies can help solve these computationally complex problems to drive efficiencies and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the use of D-Wave’s annealing quantum computers and quantum hybrid solvers in this collaboration, the potential of today’s quantum hybrid technologies to help solve the identified problems and the potential impact of solving such problems, and the role of today’s quantum technology in the construction and building sectors. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risk that these projects may not be completed successfully or at all; general economic conditions and other risks; our ability to expand our customer base and the customer adoption of our solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Cepton (NASDAQ: CPTN), LiDAR Tech Focus of Recent Proactive Video

August 4, 2023 11:32:10

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is spotlighted in a recent video release from Proactive. The interview features Brunno Moretti, Cepton’s VP of product. During the interview with Proactive’s Stephen Gunnion, Moretti discusses the implications of potential action against Chinese LiDAR companies by Washington, specifically focusing on two main concerns: national security and cybersecurity.

Moretti explained that LiDAR technology is essential for creating high-definition maps around vehicles, but when parts are produced by state-backed entities from nonallied countries, there are data security risks. He also noted the importance of a level playing field in the LiDAR industry to ensure fair competition and prevent state-subsidized companies from gaining an unfair advantage. Moretti also mentioned that Cepton is part of the LiDAR Coalition, which works to address these concerns with lawmakers, and he emphasized the importance of this work, especially as LiDAR technology is just emerging in the automotive sector.

To view the full interview, visit https://ibn.fm/dTyh2

To view the full press release, visit https://ibn.fm/90IwG

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D-perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors Business. Cepton is also engaged with all top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about this company, please visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Lexaria Bioscience (NASDAQ: LEXX) Designing Human Study of DehydraTECH-CBD for Weight Loss, Diabetes Control

August 3, 2023 11:47:46

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today reported its intention to conduct a human clinical study to examine DehydraTECH-CBD for purposes of diabetes control and weight loss. Lexaria previously announced that, in its pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following: lowered blood glucose levels by 19.9%; lowered overall body weight by 7% sustained over eight weeks; statistically significant increase in locomotor activity; lowered triglyceride levels by more than 25%; and lowered blood urea nitrogen levels by 27.9%. As a result of the very successful pre-clinical results, Lexaria is planning to undertake a diabetes clinical study to investigate whether any of these improvements are also evidenced in humans. Study design is currently underway by the company, which will be followed with submission to an independent review board to gain necessary approvals.

To view the full press release, visit https://cnw.fm/3Cc2g

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

SuperCom Ltd. (NASDAQ: SPCB) Announces Pricing for $2.75M Public Offering

August 3, 2023 11:47:16

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, Internet of Things (“IoT”) and cybersecurity sectors, announced the pricing of its current public offering of 3,235,295 units at a public offering price of $0.85 per unit. According to the announcement, each unit includes one ordinary share (or a prefunded warrant in lieu thereof) and one warrant to purchase one ordinary share. The company noted that the common warrants will be immediately exercisable at an exercise price of $0.85 per share with an expiration date five years from the date of issue. The announcement noted that gross proceeds from the public offering, which is slated to close on Aug. 3, 2023, are projected to be approximately $2.75 million before deducting placement agent fees and other offering expenses. Maxim Group LLC is acting as sole placement agent for the public offering. SuperCom also has agreed that certain existing warrants that were issued on July 25, 2022, and March 31, 2023, will be amended when this public offering closes. Amended warrants will also have an exercise price of $0.85 and will expire five years from the date of the closing of this offering.

To view the full press release, visit https://ibn.fm/H9dtz

About SuperCom Ltd.

Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification, and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secure multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one, field-proven Radio Frequency Identification (“RFID”) and mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation. For additional information about this company, please visit www.SuperCom.com.

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Freight Technologies (NASDAQ: FRGT) Joins AMACARGA, Expanding Footprint, Capabilities

August 3, 2023 11:46:58
  • Fr8Tech just announced its move to join AMACARGA to expand its capabilities to cater to the growing demands of its clients importing goods from Asia
  • The company’s association with AMACARGA affords it exceptional expertise and adherence to industry standards, bolstering its reputation in the industry
  • The move further compounds Fr8Tech’s aggressive partnerships and collaborations plan, having recently announced its association with Trucker Tools, an automated booking solutions platform

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and increasing shipper flexibility, visibility, and simplicity, just announced its move to join the Mexican Association of Cargo Agents (“AMACARGA”). This is viewed as a strategic move by the company that will expand its capabilities to cater to the growing demands of its clients importing goods from Asia (https://ibn.fm/nGMvF).

AMACARGA is the largest association of cargo agents in Mexico, an authoritative voice among Mexican and international chambers, associations, and authorities. Fr8Tech’s association with it affords it exceptional expertise and adherence to industry standards, a critical aspect in bolstering…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

CISO Global (NASDAQ: CISO) Bolsters Argo Platform to Aggregate Real-Time Data

August 3, 2023 11:46:32

CISO Global Inc. (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, has strengthened its security management platform Argo to increase the effectiveness of security teams who now can access real-time data across tool sets to make better informed decisions. The platform has the capability to aggregate data in real time from a client’s entire environment, including network asset information, currently deployed cyber tools, security operations center (“SOC”) services, vulnerability management, secure managed IT and penetration testing data. Using this information, enterprises can build individual risk profiles for each network asset to better prioritize cybersecurity threats based on asset value. “With ongoing increases to cyberattack frequency, impact, and costs of an average breach, it’s very clear that the cybersecurity industry is suffering from a widespread ineffectiveness problem,” said Chief Technology Officer Jerald Dawkins, Ph.D., CISO Global. “Argo seeks to address that issue by aggregating and curating security data from across the enterprise to not only provide context for metrics, but to pull the right information, making it actionable for our clients’ internal decision makers.”

To view the full press release, visit https://ibn.fm/42YbT

About CISO Global Inc.

CISO Global, based in Scottsdale, Arizona, is an industry leader as a managed cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services, and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Benchmark Company Raises Price Target on D-Wave Quantum Inc. (NYSE: QBTS)

August 3, 2023 11:46:06

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services and the world’s first commercial supplier of quantum computers, was featured in a recent equity research report published by The Benchmark Company LLC. The publication covers three public quantum computing companies, including D-Wave, and discusses a shifting in investor sentiment with quantum computing stocks in the report significantly outperforming the tech sector as the AI theme gathers momentum. An excerpt of the report reads, “QBTS – Our $3 price target (up from $2) is based on a 5.2x EV/Sales multiple on our current 2026E revenue projections. We believe D-Wave is the best positioned quantum computing platform to directly benefit from A.I. related demand with pre-built software to capture near-term demand opportunities.”

To view the full report, visit https://ibn.fm/Vwd5e

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory. For more information, visit the company’s website at www.DWaveSys.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Fintech Ecosystem Development (NASDAQ: FEXD) Leveraging Blockchain to Ease Cross-Border Money Transfers

August 2, 2023 11:26:14
  • FEXD is working to develop a global financial technology ecosystem comprising a network of mobile money platforms, technologies, applications, products, and services
  • The company aims to use emerging technologies like blockchain, web 3.0, AI, and the metaverse to reduce costs and accelerate the processing of money transfers, loans, and other lifestyle services
  • Blockchain is disrupting financial institutions in new ways, creating an entirely new market and an avenue to bank the unbanked
  • It offers benefits such as speed, security, accessibility, transparency, and cost reductions
  • FEXD hopes to leverage emerging technologies like blockchain to ease the process of moving money across borders

When Satoshi Nakamoto, a mysterious figure whose identity remains unknown more than a decade later, launched Bitcoin, a digital currency built on top of a peer-to-peer network that recorded transactions by “hashing them into an ongoing chain of hash-based proof-of-work” that could not be changed “without redoing the proof-of-work” (https://ibn.fm/9rYlI), they may only have had an inkling of what they had set in motion.

But as revolutionary as the idea of a digital currency backed by a proof-of-work chain, later renamed the blockchain, appears presently, it did not immediately catch on, much like most technologies. While Satoshi published their proof-of-work white paper in 2008 and launched Bitcoin at the beginning of the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

Flora Growth (NASDAQ: FLGC) Seals Deal with Hulk Hogan to Carry Exclusive Product Line

August 2, 2023 11:25:29

Flora Growth (NASDAQ: FLGC), a consumer-packaged goods leader serving all 50 states and 13 countries with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, is partnering with the world-renowned Hulk Hogan. According to the announcement, Flora Growth and Hogan, a WWE superstar, have entered into an exclusive worldwide agreement. The agreement outlines Flora Growth’s plans to produce and sell Hogan’s comprehensive consumer products portfolio globally through its Just Brands platform; anticipated products include Hulk Hogan’s hemp-derived pre-rolls, topicals, flower, edibles, CBD, HHC, Delta 8 and Kratom. “Our exclusive partnership with Flora allows us to deliver Hulk Hogan’s vision of a premier brand to the consumer,” said Hulk Hogan, the face of iconic trademarks including Hulk Hogan, Hulkamania, Hollywood Hulk Hogan and the Hulkster.

“I am excited to stand behind my brand with Flora. I used to tell my Hulkamaniacs to say their prayers, take their vitamins, and they will never go wrong. Well, let me tell you something, brother. Flora is the ideal partner to make my CBD-infused vitamins.” According to Carma HoldCo., which creates iconic global brands through licensing and was involved in the negotiations, the exclusive agreement has an initial three-year term with one-year renewal periods; the company noted that the anticipated initial 24-month, top-line sales target is $20 million, with Flora expected to pay a royalty and a license fee. “Flora is thrilled to be selected as the exclusive producer for Hulk Hogan products,” said Flora Growth CEO Clifford Starke in the press release. “Our award-winning products and Hulk Hogan’s status as an icon and American hero will make us the ultimate championship tag team.”

To view the full press release, visit https://ibn.fm/ATREV

About Flora Growth Corp.

Flora Growth is a consumer-packaged goods leader serving all 50 states with 15,000-plus points of distribution around the world and is a pharmaceutical distributor in 28 countries. In the United States, Flora’s lifestyle business has established a robust presence across all 50 states, providing the company with a solid foundation. Furthermore, the company possesses substantial potential for international expansion. Based in Germany, Flora Growth has successfully developed a strong distribution network delivering lifestyle and wellness products to 28 countries. For more information about the company, please visit www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

BiondVax Pharmaceuticals (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance

August 2, 2023 11:25:02

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, received an extension from NASDAQ to regain compliance with listing rules. The extension, which is good until Oct. 30, 2023, was granted after NASDAQ reviewed BiondVax’s detailed plan to regain compliance. BiondVax submitted the plan after receiving a May 1, 2023, deficiency letter from NASDAQ. “We are very pleased that NASDAQ has reviewed our plan and provided us the time to proceed with various initiatives already underway that alone or together will allow us to regain compliance with the shareholders’ equity listing requirement,” said BiondVax Pharmaceuticals CEO Amir Reichman in the press release. “Among other things we are pursuing a strategic partnership for our COVID-19 self-administered inhaled therapeutic/prophylactic product and advancing ahead of schedule our IL-17 NanoAb inhibitor for the treatment of autoimmune diseases such as psoriasis. This is expected to enter the clinic in 2024. . . . In addition, we decided to leverage our state-of-the-art biologics pilot manufacturing plant by commencing a new contract manufacturing and development services business unit (‘CDMO’).”

To view the full press release, visit https://ibn.fm/8T5zJ

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

ROTH MKM Raises Price Target on D-Wave Quantum (NYSE: QBTS) from $2.00 to $5.00

August 2, 2023 11:24:42

D-Wave (NYSE: QBTS), a leader in the development and delivery of quantum computing systems, software and services, was featured in a recent equity research report published by ROTH Capital Partners LLC. An excerpt of the report reads, “QBTS represents a next-generation quantum computing service provider that enables advanced applications that derive a quantum advantage over classical compute capability. QBTS’ adjusted 2Q23 and CY23 revenue expectations reflect revenue recognition timing for service contracts but is seeing no impact on customer cash collections and an improving profitability outlook. We believe investor interest in the growth opportunity in quantum computing is intensifying and raise our price target from $2.00 to $5.00. We maintain our Buy rating.”

To view the full report, visit https://ibn.fm/fjPMG

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory. For more information, visit the company’s website at www.DWaveSys.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Jupiter Wellness Inc. (NASDAQ: JUPW) Names New Advisory Board Member

August 1, 2023 11:40:05

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has announced a new member of its advisory board. David Long, cofounder and CEO of Orangetheory Fitness, has joined JUPW’s board to support the company’s launch of its newest product: Safety Shot. Long previously served on GBB Drink Lab’s advisory board, playing a key role in guiding the development and marketing of the world’s first rapid alcohol detox drink, which was recently acquired by JUPW. Long brings an impressive resume to his new board appointment. He oversaw the growth of Orangetheory Fitness to include the opening of more than 1,500 studios in 24 countries and helped the fitness company exceed $1 billion in revenues. An entrepreneur at heart, Long also provided key support in the early stages of several franchise brands including Massage Envy and European Wax Center. “We welcome David to our advisory board as he joins several key members of the Safety Shot development team who are now with Jupiter as C-level executives, advisors and board members,” said Jupiter Wellness CEO Brian John in the press release. “David’s track record in building a billion-dollar business in the fitness and wellness industry will be a great asset to Jupiter.”

To view the full press release, visit https://ibn.fm/mT0u1

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, psoriasis and vitiligo. Revenue is generated through the sales of OTC and consumer products, and licensing royalties. For additional information about this company, please visit www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) Announces ASR Deployment to Vancouver Hotel

July 31, 2023 10:09:17

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has deployed another K5 ASR; the robot was sent to a hotel in Vancouver, Washington. The new deployment is the latest in a growing number of deployments as Knightscope continues its momentum in providing safety and security in a wide array of spaces.

The impact that KSCP ASRs have on hotel security is becoming increasingly recognized. “Modern security systems, like the one deployed by Knightscope here, are conspicuous, engaging and enjoyable for guests, while providing a natural deterrence to poor decisions that may lead to more ‘official’ contact, thus reducing unwanted activities,” the company observed in the announcement.

Knightscope also announced that its authorized reseller, Transportation Solutions & Lighting, Inc. – Safety and Security Division – National Safety Systems (“NSS/TS&L”), is replenishing its inventory. NSS/TS&L placed an order for 12 new K1 Blue Light Towers in anticipation of continued growing demand for Knightscope’s emergency communication systems. This order is in addition to the 24 e-phones NSS/TS&L ordered earlier this month. “These devices allow for greater coverage, improved access and better cost control in any organization’s security program,” the company stated. “Knightscope’s leading-edge communications products and ASR services provide reliable technologies for corporate campuses to help better protect the places people live, work, study and visit.”

In addition, Knightscope is continuing the successful run of its Robot Roadshow. The event, designed to be an engaging experiential opportunity for potential clients and the general public to see in person what Knightscope offers, is slated to stop in Ontario, California, on Aug. 1–2, 2023. The roadshow will land at the Ontario Police Department and will be open from 10 a.m. to 4 p.m. PT. Participants can watch expert-led demonstrations in a climate controlled, space-age “pod,” interact directly with ASRs, test a blue light emergency phone and see the Knightscope Security Operations Center (KSOC) user interface in action.

To schedule a visit to the Robot Roadshow, visit https://ibn.fm/QKpiV

To view the full press release, visit https://ibn.fm/NdVye

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

BiondVax (NASDAQ: BVXV) Leveraging NanoAb Pipeline to Target Large Markets

July 28, 2023 13:03:12

BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company is developing a pipeline of unique nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments with large, growing markets, including dermatological conditions such as psoriasis. “BiondVax is initially targeting IL-17 [the human immune system cytokine, which is implicated in several diseases] for the treatment of psoriasis, where the market for therapeutics is expected to reach $44 billion by 2031,” reads a recent article. “The company’s plan for the IL-17 nanobody also includes addressing diseases like hidradenitis suppurativa (‘HS’), psoriatic arthritis and other large markets. BiondVax intends to use IL-17 in mild-to-moderate psoriasis patients, which comprise a higher number of patients compared to the smaller segment of severe patients [targeted in a previous competitor trial].”

To view the full article, visit https://ibn.fm/BmIqW

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine Study

July 28, 2023 13:02:44

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has incorporated a new wholly owned subsidiary: Lexaria Nutraceutical Corp., or LEXX Nutra. According to the announcement, LEXX Nutra was established to support Lexaria’s overall strategy of maximizing the potential for its patented DehydraTECH(TM) technology in a variety of markets. The company issued an exclusive perpetual license to LEXX Nutra, giving the new subsidiary rights to utilize, or sublicense the use of, DehydraTECH in an array of ways, including creating consumer packaged goods (“CPG”) and/or intermediate ingredients composed of any molecule except those associated with nicotine or cannabis. LEXX Nutra is prohibited from using its license for the manufacture of any pharmaceutical product. The company also reported that dosing for its human oral nicotine study NIC-H22-1 was completed on May 8, 2023, and data amalgamation and analysis has started. Lexaria anticipates releasing results from the study in the next two weeks. The study is a human pharmacokinetic randomized, double-blinded, crossover study conducted with a minimum of 36 human volunteers who are current cigarette smokers.

To view the full press release, visit https://ibn.fm/AIzgm

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

Genprex (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China

July 28, 2023 13:02:10
  • Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers
  • The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda
  • The company has received patent protection for the REQORSA-Keytruda drug combination in the U.S., Japan, Australia, Russia, Mexico, and China, meaning the company has secured exclusivity in many of the largest markets
  • The granted patents, three Fast Track Designations, and positive preclinical and clinical data are poised to help the company accelerate its clinical development of REQORSA in its various development programs

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company on a mission to develop life-changing therapies for patients with cancer and diabetes, recently received a patent in China – Genprex China Patent No: 201780076886.X – from the China National Intellectual Property Administration. The granted patent broadly covers the use of the company’s drug candidate REQORSAI immunogene therapy in combination with PD-1 antibodies, such as KeytrI(R), to treat cancers (https://ibn.fm/AD3iX).

The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed after…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Freight Technologies (NASDAQ: FRGT) Keeping a Close Eye on FMCSA Speed Limiter Rule

July 27, 2023 11:44:16
  • The FMCSA (Federal Motor Carrier Safety Administration) proposed a rule mandating speed limiters for most commercial vehicles
  • The ATA has supported the move, while OOIDA (Owner Operator Independent Drivers Association) has opposed it, terming it as an attempt to eliminate one of the few advantages they enjoy over big business
  • The FMCSA is yet to communicate its decision on the matter, pending its review of over 15,000 comments on the issue

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility, and simplicity, is closely monitoring the developing situation with speed limiter directives on commercial vehicles. As a company heavily invested in the industry, such a directive could impact its performance and service delivery.

The Federal Motor Carrier Safety Administration (“FMCSA”) proposed a rule that would mandate speed limiters for most commercial vehicles. While the exact speed has not been confirmed, safety groups have proposed a 60 mph limit for heavy-duty trucks. This is not the first time such a proposal has been…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

HeartBeam Inc. (NASDAQ: BEAT) to Host Q2 2023 Results Call, Webcast

July 27, 2023 11:43:54

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced that it will hold a conference call to discuss its results for the second quarter ended June 30, 2023. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno and CFO Richard Brounstein will host the call at 4:30 p.m. Eastern Time on Thursday, Aug. 10, 2023. Topics will include a review of recent announcements, ongoing initiatives and key 2023 milestones, followed by a question-and-answer period. Interested parties can visit https://ibn.fm/fiRyL to register for and access the webcast and join the call by dialing 1-877-704-4453 or 1-201-389-0920 (international) and entering code 13739569. A presentation will accompany the conference call, which can be viewed during the webcast or accessed via the investor relations section of the company’s website. A telephone replay will be available approximately two hours after the call as detailed in the announcement.

To view the full press release, visit https://ibn.fm/YX0uj

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

D-Wave Quantum (NYSE: QBTS) to Participate in Quantum Computing Webinar, New Research Collaborations

July 27, 2023 11:43:36

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, will participate in Deloitte’s upcoming quantum computing webinar series. The episode, slated for Aug. 3, 2023, is titled “Quantum Annealing Unleashed: Optimize Your Business Operations” and will feature a discussion by Murray Thom, D-Wave vice president of quantum business innovation; Scott Buchholz, global quantum lead at Deloitte Consulting LLP; and Sal Certo, quantum optimization lead at Deloitte. The 60-minute webinar will begin at noon ET. The hour-long event will include a discussion on annealing quantum computing’s near-term value and will include real-world use cases that show the technology’s role in fueling operational excellence.

In addition, D-Wave announced two new collaborations facilitate key hardware research programs for quantum computing systems. D-Wave is working with the Institute for Quantum Computing (“IQC”) at the University of Waterloo on these research projects, funded by the Natural Sciences and Engineering Research Council of Canada (“NSERC”) Quantum Alliance program. According to the announcement, the focus will be on identifying improvements in device design and materials quality that support increasingly coherent superconducting quantum processors.

“Quantum computing has the potential to revolutionize how we tackle societal problems,” said D-Wave Quantum CEO Dr. Alan Baratz in the press release. “Key to this transformation is the ability to provide larger quantum systems with greater coherence, and these NSERC projects each facilitate important R&D for these next-generation systems. We’re excited to engage with the University of Waterloo through the NSERC program to further build out a robust quantum ecosystem that can tackle real-world problems.”

To view the Deloitte presentation, visit https://ibn.fm/xJJhm

To view the full press releases, visit https://ibn.fm/5K4iW and https://ibn.fm/oZRL4

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California and Los Alamos National Laboratory. For more information about the company, please visit www.DWaveSys.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About BillionDollarClub

BillionDollarClub (BDC) is the exclusive home of the biggest and brightest companies covered by IBN, a financial news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution to millions of social media followers, and (5) a full array of corporate communications solutions. This is the place you want to be, where every covered company has a market cap in excess of $1 billion. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled visibility, recognition and brand awareness. While IBN’s client list includes companies big and small, BillionDollarClub is the gold standard.

To receive SMS text alerts from BillionDollarClub, text “Billion” to 844-397-5787  (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: http://IBN.fm/Disclaimer

BillionDollarClub (BDC)
Los Angeles, California
www.BillionDollarClub.com
310.299.1717 Office
[email protected]

BillionDollarClub is part of the InvestorBrandNetwork.

Lexaria Bioscience’s (NASDAQ: LEXX) DehydraTECH(TM) Set to be Used in Multi-Billion Dollar Markets

July 26, 2023 12:34:43
  • Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats
  • This unique approach to drug delivery has earned Lexaria a total of 35 patents, with many patents pending worldwide
  • The company continues active discussions with multi-billion dollar companies for the potential use of DehydraTECH in their commercial pursuits
  • Lexaria is also actively seeking commercial partners during 2023 and 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is out on an ambitious move to address conditions with high unmet needs. This focus has allowed them to make strides in the potential treatment of conditions such as hypertension, epilepsy, human hormone delivery, and nicotine replacement; all made possible through its patented technology, DehydraTECH(TM).

DehydraTECH enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats. The technology serves as an additional step that can be easily incorporated into any formulation and manufacturing process, allowing for speedy delivery, an increase…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

M&A Activity, Sales of Anti-IL-17 Drugs Suggest Upside Potential for BiondVax Pharmaceuticals (NASDAQ: BVXV)

July 26, 2023 12:34:01
  • BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price
  • The report discussed Eli Lilly’s announcement of a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion as evidence of the potential value of BiondVax in this segment of the therapeutics market
  • DICE Therapeutics is currently evaluating its lead drug candidate, DC-806, an oral IL-17 inhibitor, in a Phase II trial, with early-stage results from the Phase I study showing a near-44% reduction in Psoriasis Area and Severity Index
  • The report noted that the deal between Eli Lilly and DICE Therapeutics illustrates the potential valuation that BiondVax could receive with positive early-stage clinical results
  • Also, revenues from FDA-approved psoriasis drugs show the potential value of the company should its IL-17 NanoAb therapy eventually receive FDA approval

According to Goldman Sachs Research, the global pharmaceutical industry is sitting on about $700 billion in dealmaking firepower, expected to fuel M&A-driven growth as companies look to revamp their intellectual property portfolio as their existing patents expire (https://ibn.fm/7VNq6). Flush with cash, big drugmakers also have easy access to alternative financing, factors that allow them to make aggressive acquisition bids for promising biotechnology companies and other targets (https://ibn.fm/Uo69R).

This played out recently when Eli Lilly and Company (NYSE: LLY) announced it had signed a definitive agreement with DICE Therapeutics, Inc. (NASDAQ: DICE) to acquire DICE (https://ibn.fm/CPCbR) in a deal valued at approximately $2.4 billion. DICE is a biopharmaceutical company that develops novel oral…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Names Experienced Physician, Researcher to Board of Directors

July 26, 2023 12:33:15

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has announced a new member of its board of directors: Michael R. Jaff, DO. This appointment brings the number of board members to eight. A renowned vascular physician and researcher, Jaff has an impressive background in the clinical and industry space. He will add “a unique and extremely valuable perspective that is crucial for HeartBeam as we progress toward our initial clearances and the commercial availability of our technology,” the announcement stated. Currently the chief medical officer and vice president of Clinical Affairs, Technology and Innovation of the Peripheral Interventions division at Boston Scientific Corporation, Jaff has also been a professor of medicine at Harvard Medical School, president of Newton-Wellesley Hospital, and the inaugural Paul and Phyllis Fireman endowed chair of vascular medicine and medical director of the Fireman Vascular Center at the Massachusetts General Hospital. A recognized expert in vascular medicine, he founded VasCore, the Vascular Ultrasound Core Laboratory, and is the author of more than 300 peer-reviewed publications and 10 textbooks. “Dr. Jaff brings an extraordinary level of expertise to the HeartBeam board, with his extensive experience as a researcher, practicing clinician, hospital administrator and industry executive,” said HeartBeam executive chair Rich Ferrari in the press release. “His tremendous knowledge in clinical trial design and execution, as well as his experience supporting novel technologies in front of the Food and Drug Administration, will be valuable for the company.”

To view the full press release, visit https://ibn.fm/cJ7oh

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen (NASDAQ: MULN) Announces Bollinger’s Receipt of $3M Grant from Michigan

July 26, 2023 12:32:56

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that Bollinger Motors received final approval from the state of Michigan for a $3 million grant aimed at promoting job creation in the state. In a unanimous decision, the Michigan Strategic Fund Board approved the incentive through the Michigan Business Development Program. “Bollinger Motors is poised for growth and we’re proud to be focused on expanding our company’s operations as we approach start-of-production,” said Robert Bollinger, founder and CEO of Bollinger Motors. “I appreciate Michigan’s faith in our plan and our product as we seek to electrify America’s fleets.”

To view the full news release, visit https://ibn.fm/cqy9J

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greencarstocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greencarstocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.greencarstocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Knightscope, Inc. (NASDAQ: KSCP) KAP Deploys K5 to San Diego Residential Community

July 25, 2023 11:35:42

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced that Knightscope Authorized Partner (“KAP”) JDS Security deployed its first of four K5 ASRs at a multifamily apartment community in San Diego, California.

The announcement reads, “This new client is one of the top multifamily housing owners, developers and property managers in the U.S., as ranked by the National Multifamily Housing Council (‘NMHC’). The company has over 37 years in the multifamily sector, has acquired or developed 1,015 communities consisting of over 285,000 units and almost $40 billion in total project costs with current property management at 41,000 units in over 30 markets nationally (as of Sept. 30, 2022). Clients with such strong portfolios offer great expansion opportunities for Knightscope as the company continues to execute on its growth plan.”

To view the full press release, visit https://ibn.fm/UdX3z

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.

BiondVax’s (NASDAQ: BVXV) CDMO Services Meet Needs of Pharma, Biotech Companies of All Sizes

July 25, 2023 11:35:09

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company recently showcased its boutique end-to-end contract development and manufacturing organization (“CDMO”) services and expertise at a leading conference for International Life Science and HealthTech industries, the Biomed Conference, in Tel Aviv. “These CDMO services will allow BiondVax to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services, leveraging its Good Manufacturing Practices (‘GMP’) biologics manufacturing facility in Jerusalem… The company’s CDMO services are designed to meet the needs of pharmaceutical and biotechnology companies of all sizes, with a commitment to providing customers with the highest levels of quality and service,” a recent article reads. “‘Offering CDMO services allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,’ BiondVax CEO Amir Reichman said in a year-end letter to stakeholders… Adding the CDMO services will keep the team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb focus – targeting COVID-19, psoriasis, asthma, and more.”

To view the full article, visit https://ibn.fm/2bIqm

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

FingerMotion (NASDAQ: FNGR) CEO Featured in C-Level Interview with BestGrowthStocks.Com

July 25, 2023 11:34:23

FingerMotion’s (NASDAQ: FNGR) CEO Martin J. Shen was featured in an interview with Best Growth Stocks, a leading independent equity research and corporate access firm focused on small and mid-cap growth companies. During the interview, Best Growth Stocks Senior Editor Steve Macalbry and Shen discuss an overview of the company, building shareholder value, eliminating convertible debt, recent company news, strategy details, and much more. “In our Big Data division, we have grown our partnerships with both Pacific Life Re and Munich Re, although we acknowledge that the progress is not at the speed that we would like. Operationally, we must expect some growing pains but we continue to move forward and improve – this has always been our long-term focus and the division is poised to be the major contributor to our business in the near future,” Shen said. “As noted throughout, we have a number of exciting new ventures that could provide additional revenue growth and expand our business to new industries. At the same time, we remain committed to growing our current businesses to their full potential, understanding that a strong foundation will provide us the best footing to grow.”

To view the full press release, visit https://ibn.fm/BViYW

About FingerMotion Inc.

FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. It is one of only a few companies in China with access to wholesale rechargeable minutes from China’s largest mobile phone providers to service its consumers. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve over 1 billion users in the China market and eventually expand the model to other regional markets. For more information about the company, visit www.Fingermotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

McEwen Mining (NYSE: MUX) (TSX: MUX) Leveraging Updated Strategy for Los Azules Project

July 25, 2023 11:33:57

McEwen Mining (NYSE: MUX) (TSX: MUX), an asset-rich diversified gold and copper producer that owns 52% of McEwen Copper, recently released the results of an updated Preliminary Economic Assessment (“2023 PEA”) on the 100% McEwen Copper-owned Los Azules Project in San Juan, Argentina. The 2023 PEA documented “updated base case development strategy, which is starkly different from that presented in the previous PEA published in 2017, as well as an updated independent mineral resource estimate,” a recent article reads. “The selection of the updated implementation strategy rode on three primary principles, chief among them the environmental footprint. Compared to the conventional milling and treatment strategy in the 2017 PEA, the proposed heap leach project is set to reduce fresh water consumption by approximately 75% (from 600 to 150 L/s) and electricity consumption by about 75% (from 230 to 57 MW). The updated strategy is also expected to reduce scope 1 and 2 greenhouse gas (‘GHG’) emissions by approximately 57% from 1,560 to 670 CO2e/t Cu. McEwen Copper is also considering paths to further reduce GHG emissions by implementing new technologies, with the goal of reaching net-zero carbon by 2038 with some offsets… The company is confident this strategy will make the Los Azules copper cathodes attractive to end users looking to measurably reduce their upstream environmental impacts.”

To view the full article, visit https://ibn.fm/4A094

About McEwen Mining Inc.

McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, it has significant exposure to copper through its 52% ownership of McEwen Copper. The company’s goal is to improve the productivity and extend the life of its mines with the objective of increasing its share value and price and providing a yield. Rob McEwen, chairman and chief owner, has personal investment in the company of US$220 million. His annual salary is US$1.For more information about the company, visit www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.miningnewswire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.miningnewswire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.miningnewswire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

D-Wave Quantum (NYSE: QBTS) Accelerates Commercial Quantum Adoption As Interest in Quantum Computing Grows

July 25, 2023 11:33:21
  • D-Wave is working with a portfolio of impressive commercial customers including Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, and many more
  • Governments worldwide are calling for the implementation of quantum applications – with the United States pushing for development and deployment of quantum applications within the next 24 months
  • D-Wave, the world’s first commercial quantum computing solutions supplier, is successfully filling the increasing quantum needs of customers along with the growing interest of the government for expanding quantum technology

D-Wave Quantum (NYSE: QBTS), a leader in commercial quantum computing systems, software, and services, continues to provide customers clear value via practical quantum and quantum-hybrid applications that solve real-world problems in the areas of logistics, artificial intelligence, materials sciences, drug discovery, scheduling, and financial modeling. The company delivers these applications to a portfolio of blue-chip industry leaders that include Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, and more – reflecting the growing interest and adoption of today’s quantum annealing technology among forward-looking companies.

D-Wave’s quantum technology has been applied to a multitude of computationally complex problems, from grocery store optimization to protein design. Groovenauts and Mitsubishi Estate utilized quantum annealing to optimize waste collection and reduce carbon dioxide emissions by…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the release and performance of the Advantage2 processor. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.

Fintech Ecosystem Development (NASDAQ: FEXD) Announces Date Extension to Complete Business Combination

July 24, 2023 11:47:54

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) today announced that its board of directors has decided to extend the date by which the company must consummate an initial business combination (the “deadline date”) from July 21, 2023, for an additional month, to August 21, 2023. The company’s sponsor, Revofast LLC, deposited $110,000 into its trust account in connection with the extension, the fourth of twelve potential one-month extensions of the deadline date available to the company. According to the update, the company’s amended and restated certificate of incorporation, as amended (the “charter”), provides the company with the right to extend the deadline date up to twelve times for an additional one month each time (each, an “extension”), from April 21, 2023, to April 21, 2024.

To view the full press release, visit https://ibn.fm/eHnrZ

About Fintech Ecosystem Development Corp.

Fintech Ecosystem Development is a special purpose acquisition company formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector. The company is sponsored by Revofast LLC and the management team led by CEO, president and founder Dr. Saiful Khandaker and a group of experienced fintech business and technology innovators. For more information about the company, please visit www.FintechEcosys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

McEwen Mining (NYSE: MUX) (TSX: MUX) Reports Additional Copper Values at Los Azules

July 24, 2023 11:47:08
  • McEwen just reported new copper assays at its Los Azules project in San Juan, Argentina, the 9th largest undeveloped copper deposit in the world
  • These results lead the company closer to realizing the full extent and economic potential of the deposit
  • The latest drilling program, which began in October 2022 and concluded on June 19, 2023, has attracted new investment capital at rates implying a significant boost in the company’s value
  • McEwen’s management is confident a future mine would support annual production of 415 million pounds of copper during its first 13 years at Los Azules, while creating long-term and sustainable value for its shareholders and all stakeholders

McEwen Mining (NYSE: MUX) (TSX: MUX), an asset-rich, diversified gold and silver producer in the Americas, on July 12th reported additional copper assays at its Los Azules project in San Juan, Argentina. Recent infill and other resource drilling completed since the data cut-off for the 2023 Preliminary Economic Assessment (“PEA”) highlights the strength of the resource model by directly comparing new assay results to the resource model prediction for the same area. A high level of predictability in the resource model represents an important milestone for McEwen and its efforts towards tapping into this vast resource (https://ibn.fm/qGfzj).

Over the course of the latest drill program, which began in October 2022 and concluded on June 19, 2023, up to 15 rigs completed some 39,900 m of drilling in 138 holes and have expanded the overall drill hole database to 126,000 m. Each hole serves to evaluate and de-risk…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.miningnewswire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.miningnewswire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.miningnewswire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

Freight Technologies (NASDAQ: FRGT) Collaboration Boosts Strength of Shipping Networks in US

July 24, 2023 11:46:44
  • Freight Technologies (aka Fr8Tech) is a growing commercial freight transportation technology developer whose flagship Fr8App platform helps shippers and carriers easily match loads and destinations in the USMCA
  • Trucker Tools is a trip planning, shipment visibility, predictive freight matching and automated booking solutions company that has developed its flagship Smart Capacity(R) platform
  • Fr8Tech recently announced integration of Trucker Tools’ network, boosting the pool of truck drivers able to use Fr8App by more than 315,000 carriers
  • The collaboration is expected to increase the offers on loads by 75 percent and grow the carrier network for loads originating from and destined to locations within the United States by as much as twentyfold

Supply chain innovator Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has expanded the reach of its modern technology platform by welcoming an extensive new pool of truck drivers working within the United States-Mexico-Canada Agreement (“USMCA”) trade area, increasing the ability of commercial freight transportation networks to manage shipping loads of all sizes.

Freight Technologies, aka Fr8Tech, recently announced completion of its collaboration with automated booking solutions platform Trucker Tools, integrating Trucker Tools’ extensive network of over…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TechMediaWire

TechMediaWire (“TMW”) is a tech-focused financial news and content distribution company, one of 50+ brands within IBN, providing: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a specialized communications platform with an extensive team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public tech companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By putting a spotlight on the latest and greatest in the tech industry, TMW brings its clients unparalleled visibility, recognition and brand awareness. TMW is where investors come to learn about the next big things in tech and the companies that are making them happen.

To receive SMS text alerts from TechMediaWire, text “TECH” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://TechMediaWire.com/disclaimer

TechMediaWire (TMW)
Los Angeles, CA
www.TechMediaWire.com
212.418.1217 Office
[email protected]

TechMediaWire is part of IBN.